WO2022127847A1 - Dérivé de pyrimidone et son utilisation dans un médicament - Google Patents
Dérivé de pyrimidone et son utilisation dans un médicament Download PDFInfo
- Publication number
- WO2022127847A1 WO2022127847A1 PCT/CN2021/138693 CN2021138693W WO2022127847A1 WO 2022127847 A1 WO2022127847 A1 WO 2022127847A1 CN 2021138693 W CN2021138693 W CN 2021138693W WO 2022127847 A1 WO2022127847 A1 WO 2022127847A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- isopropyl
- oxo
- mmol
- chf
- och
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 title abstract description 6
- 150000008318 pyrimidones Chemical class 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 309
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 102200006538 rs121913530 Human genes 0.000 claims abstract description 19
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 230000001404 mediated effect Effects 0.000 claims abstract description 9
- -1 hydrate Substances 0.000 claims description 247
- 125000000217 alkyl group Chemical group 0.000 claims description 126
- 125000003545 alkoxy group Chemical group 0.000 claims description 111
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 105
- 229910052805 deuterium Inorganic materials 0.000 claims description 105
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 83
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 70
- 125000004043 oxo group Chemical group O=* 0.000 claims description 68
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 66
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 63
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 61
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 60
- 229910052736 halogen Inorganic materials 0.000 claims description 60
- 150000002367 halogens Chemical class 0.000 claims description 60
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 45
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 44
- 229910052757 nitrogen Inorganic materials 0.000 claims description 43
- 125000004429 atom Chemical group 0.000 claims description 42
- 125000003118 aryl group Chemical group 0.000 claims description 41
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 39
- 239000000460 chlorine Substances 0.000 claims description 39
- 125000000623 heterocyclic group Chemical group 0.000 claims description 38
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 38
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 37
- 229910052801 chlorine Inorganic materials 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- 239000001257 hydrogen Substances 0.000 claims description 37
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 35
- 229910052731 fluorine Inorganic materials 0.000 claims description 35
- 239000011737 fluorine Substances 0.000 claims description 35
- 150000002431 hydrogen Chemical group 0.000 claims description 35
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 34
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 34
- 229910052794 bromium Inorganic materials 0.000 claims description 34
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 34
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 33
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 32
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 32
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 30
- 125000003282 alkyl amino group Chemical group 0.000 claims description 29
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 29
- 125000001072 heteroaryl group Chemical group 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 28
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 27
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 27
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 27
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 26
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 26
- 125000000304 alkynyl group Chemical group 0.000 claims description 25
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 24
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 24
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 24
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 22
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 22
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 22
- 125000004193 piperazinyl group Chemical group 0.000 claims description 21
- 125000003342 alkenyl group Chemical group 0.000 claims description 20
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 20
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 20
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 20
- 125000002757 morpholinyl group Chemical group 0.000 claims description 20
- 125000003386 piperidinyl group Chemical group 0.000 claims description 20
- 239000000651 prodrug Substances 0.000 claims description 18
- 229940002612 prodrug Drugs 0.000 claims description 18
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 17
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 16
- 125000004122 cyclic group Chemical group 0.000 claims description 15
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 15
- 125000002950 monocyclic group Chemical group 0.000 claims description 14
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 13
- 125000004076 pyridyl group Chemical group 0.000 claims description 13
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 13
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 12
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 12
- 125000002541 furyl group Chemical group 0.000 claims description 12
- 125000002883 imidazolyl group Chemical group 0.000 claims description 12
- 239000002207 metabolite Substances 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 12
- 125000000335 thiazolyl group Chemical group 0.000 claims description 12
- 125000001544 thienyl group Chemical group 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 11
- 125000001425 triazolyl group Chemical group 0.000 claims description 11
- 125000003566 oxetanyl group Chemical group 0.000 claims description 10
- 125000002053 thietanyl group Chemical group 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 7
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 7
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 125000002393 azetidinyl group Chemical group 0.000 claims description 6
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 claims description 6
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 6
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 6
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 125000003003 spiro group Chemical group 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 206010038038 rectal cancer Diseases 0.000 claims description 5
- 201000001275 rectum cancer Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 239000007983 Tris buffer Substances 0.000 claims description 4
- 150000001335 aliphatic alkanes Chemical group 0.000 claims description 4
- 201000007983 brain glioma Diseases 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 4
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 claims description 3
- 206010073360 Appendix cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 3
- 208000021780 appendiceal neoplasm Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000002313 intestinal cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 125000000033 alkoxyamino group Chemical group 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 21
- 208000024891 symptom Diseases 0.000 abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 399
- 238000006243 chemical reaction Methods 0.000 description 384
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 371
- 230000002829 reductive effect Effects 0.000 description 193
- 238000003786 synthesis reaction Methods 0.000 description 163
- 239000007787 solid Substances 0.000 description 161
- 238000000132 electrospray ionisation Methods 0.000 description 156
- 150000002500 ions Chemical class 0.000 description 155
- 238000004949 mass spectrometry Methods 0.000 description 155
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 147
- 235000019439 ethyl acetate Nutrition 0.000 description 147
- 230000015572 biosynthetic process Effects 0.000 description 145
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 114
- 238000010898 silica gel chromatography Methods 0.000 description 111
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 81
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 72
- 239000004698 Polyethylene Substances 0.000 description 71
- 239000012074 organic phase Substances 0.000 description 66
- 238000005481 NMR spectroscopy Methods 0.000 description 63
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 57
- 229910001868 water Inorganic materials 0.000 description 56
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 52
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 52
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 49
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 43
- 239000000203 mixture Substances 0.000 description 43
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 42
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 41
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 36
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 35
- 239000000243 solution Substances 0.000 description 34
- 125000004432 carbon atom Chemical group C* 0.000 description 33
- 235000002639 sodium chloride Nutrition 0.000 description 33
- 125000001424 substituent group Chemical group 0.000 description 33
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 229920000728 polyester Polymers 0.000 description 29
- 235000011056 potassium acetate Nutrition 0.000 description 26
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 25
- 239000002994 raw material Substances 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 229910052760 oxygen Inorganic materials 0.000 description 20
- 125000006413 ring segment Chemical group 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
- MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 16
- 239000001301 oxygen Chemical group 0.000 description 13
- 229910052717 sulfur Inorganic materials 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000004440 column chromatography Methods 0.000 description 12
- 125000005842 heteroatom Chemical group 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 239000003937 drug carrier Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 125000002619 bicyclic group Chemical group 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000003208 petroleum Substances 0.000 description 10
- 229910052698 phosphorus Inorganic materials 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- 229940086542 triethylamine Drugs 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 9
- HDMPPCVRRVKQAP-UHFFFAOYSA-N 4,6,7-trichloro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2-one Chemical compound ClC=1C2=C(N(C(N=1)=O)C=1C(=NC=CC=1C)C(C)C)N=C(C(=C2)Cl)Cl HDMPPCVRRVKQAP-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- LGIBDQRYOFBMTC-UHFFFAOYSA-N dnc010031 Chemical compound C1=CC(O)=CC=C1C1C(=O)NC2=CC=CC=C2C2=C3C1=CNC3=NC=C2 LGIBDQRYOFBMTC-UHFFFAOYSA-N 0.000 description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 102100030708 GTPase KRas Human genes 0.000 description 7
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 7
- 239000012391 XPhos Pd G2 Substances 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- RSLSVURFMXHEEU-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[3-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane;2-phenylaniline Chemical compound [Pd+]Cl.NC1=CC=CC=C1C1=CC=CC=[C-]1.CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC(P(C2CCCCC2)C2CCCCC2)=C1 RSLSVURFMXHEEU-UHFFFAOYSA-M 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- ZLODKAZZRDLUKX-UHFFFAOYSA-N (2-fluoro-5-methylphenyl)boronic acid Chemical compound CC1=CC=C(F)C(B(O)O)=C1 ZLODKAZZRDLUKX-UHFFFAOYSA-N 0.000 description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 5
- OXVRPHSSBIEWCC-YADHBBJMSA-N 4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-7-(2-fluoro-5-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=C(C)C=C1)=C1F)C(C#N)=C1)=C1C(N(C[C@H]1C)[C@@H](C)CN1C(C=C)=O)=N1)C1=O OXVRPHSSBIEWCC-YADHBBJMSA-N 0.000 description 5
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 125000002009 alkene group Chemical group 0.000 description 5
- 125000002355 alkine group Chemical group 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000003419 tautomerization reaction Methods 0.000 description 5
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 5
- ROEQGIFOWRQYHD-UHFFFAOYSA-N (2-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC=C1B(O)O ROEQGIFOWRQYHD-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 4
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 4
- 125000004452 carbocyclyl group Chemical group 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- RIVIDPPYRINTTH-UHFFFAOYSA-N n-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 4
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- UQMOSSMYPIJNTO-UHFFFAOYSA-N (2-hydroxy-3-methylphenyl)boronic acid Chemical compound CC1=CC=CC(B(O)O)=C1O UQMOSSMYPIJNTO-UHFFFAOYSA-N 0.000 description 3
- OFEGIRFEEMWYRA-UHFFFAOYSA-N 6-bromo-7-iodo-1-(4-methyl-2-propan-2-ylpyridin-3-yl)quinazoline-2,4-dione Chemical compound CC(C)C1=NC=CC(C)=C1N(C(C(C(N1)=O)=C2)=CC(I)=C2Br)C1=O OFEGIRFEEMWYRA-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000004103 aminoalkyl group Chemical group 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 3
- 108700042226 ras Genes Proteins 0.000 description 3
- 102000016914 ras Proteins Human genes 0.000 description 3
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- QLEHMPQAIIWWBK-DLBZAZTESA-N tert-butyl (2R,5S)-4-[6,7-dichloro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-2,5-dimethylpiperazine-1-carboxylate Chemical compound C1=NC(C(C)C)=C(N2C(=O)N=C(C3=CC(=C(N=C23)Cl)Cl)N2[C@@H](C)CN(C(=O)OC(C)(C)C)[C@@H](C2)C)C(C)=C1 QLEHMPQAIIWWBK-DLBZAZTESA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- VEHQHYJZLSODOU-UHFFFAOYSA-N (2-fluoro-3-methylphenyl)boronic acid Chemical compound CC1=CC=CC(B(O)O)=C1F VEHQHYJZLSODOU-UHFFFAOYSA-N 0.000 description 2
- QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 2
- LFTDNVANQJMILC-UHFFFAOYSA-N 2,5,6-trichloro-N-[(4-methyl-2-propan-2-ylpyridin-3-yl)carbamoyl]pyridine-3-carboxamide Chemical compound ClC1=C(C(=O)NC(NC=2C(=NC=CC=2C)C(C)C)=O)C=C(C(=N1)Cl)Cl LFTDNVANQJMILC-UHFFFAOYSA-N 0.000 description 2
- DBAVDGXPOXFHRC-UHFFFAOYSA-N 2,5,6-trichloropyridine-3-carboxamide Chemical compound NC(=O)C1=CC(Cl)=C(Cl)N=C1Cl DBAVDGXPOXFHRC-UHFFFAOYSA-N 0.000 description 2
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 2
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 2
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 2
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 2
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 2
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- QDTAKKTXRHWDGW-UXHICEINSA-N 4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-7-(1,3-dimethylpyrazol-4-yl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C1=CN(C)N=C1C)C(C#N)=C1)=C1C(N(C[C@H]1C)[C@@H](C)CN1C(C=C)=O)=N1)C1=O QDTAKKTXRHWDGW-UXHICEINSA-N 0.000 description 2
- LHVNJYSJQOBIKX-PKTZIBPZSA-N 4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-7-(2-methoxy-3-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1C)=C1OC)C(C#N)=C1)=C1C(N(C[C@H]1C)[C@@H](C)CN1C(C=C)=O)=N1)C1=O LHVNJYSJQOBIKX-PKTZIBPZSA-N 0.000 description 2
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 2
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 2
- VXPOAPWLMVAUCK-UHFFFAOYSA-N 4-methyl-2-propan-2-ylpyridin-3-amine Chemical compound C(C)(C)C1=NC=CC(=C1N)C VXPOAPWLMVAUCK-UHFFFAOYSA-N 0.000 description 2
- HUEVVDQPENPYSW-UHFFFAOYSA-N 5-bromo-2-fluoro-4-iodo-N-[(4-methyl-2-propan-2-ylpyridin-3-yl)carbamoyl]benzamide Chemical compound CC(C)C1=NC=CC(C)=C1NC(NC(C(C=C(C(I)=C1)Br)=C1F)=O)=O HUEVVDQPENPYSW-UHFFFAOYSA-N 0.000 description 2
- PHUDPPBJBBSDTI-UHFFFAOYSA-N 5-bromo-2-fluoro-4-iodobenzamide Chemical compound NC(C(C=C(C(I)=C1)Br)=C1F)=O PHUDPPBJBBSDTI-UHFFFAOYSA-N 0.000 description 2
- HDXIZUYCJWJRCG-UHFFFAOYSA-N 6-bromo-4-chloro-7-iodo-1-(4-methyl-2-propan-2-ylpyridin-3-yl)quinazolin-2-one Chemical compound CC(C)C1=NC=CC(C)=C1N(C(C(C(Cl)=N1)=C2)=CC(I)=C2Br)C1=O HDXIZUYCJWJRCG-UHFFFAOYSA-N 0.000 description 2
- VBMKXBRFMWNISA-UHFFFAOYSA-N 7-(2-methoxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxo-4-(2-prop-2-enoyl-2,7-diazaspiro[4.4]nonan-7-yl)pyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1)=C1OC)C(C#N)=C1)=C1C(N(CC1)CC1(CC1)CN1C(C=C)=O)=N1)C1=O VBMKXBRFMWNISA-UHFFFAOYSA-N 0.000 description 2
- OGFBAOUCQWTWAF-UXHICEINSA-N 7-cyclohexyl-4-[(2S,5R)-2,5-dimethylpiperazin-1-yl]-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C1CCCCC1)C(C#N)=C1)=C1C(N1[C@@H](C)CN[C@H](C)C1)=N1)C1=O OGFBAOUCQWTWAF-UXHICEINSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- ROZPTLCRLSXZDA-UHFFFAOYSA-N BrC=1C(=CC(=C(C(=O)O)C1)F)I Chemical compound BrC=1C(=CC(=C(C(=O)O)C1)F)I ROZPTLCRLSXZDA-UHFFFAOYSA-N 0.000 description 2
- BQNADONQXRVNKK-UHFFFAOYSA-N BrC=1C(=CC(=C(C(=O)OC)C1)F)I Chemical compound BrC=1C(=CC(=C(C(=O)OC)C1)F)I BQNADONQXRVNKK-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 101150105104 Kras gene Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 101150040459 RAS gene Proteins 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- UJQAHAANAPEYLR-UHFFFAOYSA-N [2-chloro-6-[2,4,6-tri(propan-2-yl)phenyl]phenyl]-dicyclohexylphosphane Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC(Cl)=C1P(C1CCCCC1)C1CCCCC1 UJQAHAANAPEYLR-UHFFFAOYSA-N 0.000 description 2
- NDQKGYXNMLOECO-UHFFFAOYSA-N acetic acid;potassium Chemical compound [K].CC(O)=O NDQKGYXNMLOECO-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- JOCYKKRVIIGZJH-UHFFFAOYSA-N methyl 4-amino-5-bromo-2-fluorobenzoate Chemical compound COC(C1=C(C=C(C(=C1)Br)N)F)=O JOCYKKRVIIGZJH-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 150000003254 radicals Chemical group 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- JKFLEAXVOGMLKO-XZOQPEGZSA-N tert-butyl (2R,5S)-4-[6-cyano-7-(2-fluoro-3-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-2,5-dimethylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1C)=C1F)C(C#N)=C1)=C1C(N(C[C@H]1C)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)C1=O JKFLEAXVOGMLKO-XZOQPEGZSA-N 0.000 description 2
- PGZCVLUQTJRRAA-DTWKUNHWSA-N tert-butyl (2r,5s)-2,5-dimethylpiperazine-1-carboxylate Chemical compound C[C@H]1CN(C(=O)OC(C)(C)C)[C@H](C)CN1 PGZCVLUQTJRRAA-DTWKUNHWSA-N 0.000 description 2
- ONLHRXHDBUNWKH-FQEVSTJZSA-N tert-butyl (3S)-4-[6-chloro-7-(2-fluoro-5-methoxycarbonylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-3-methylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=C(C=C1)C(OC)=O)=C1F)C(Cl)=C1)=C1C(N(CC1)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)C1=O ONLHRXHDBUNWKH-FQEVSTJZSA-N 0.000 description 2
- FMLPQHJYUZTHQS-QMMMGPOBSA-N tert-butyl (3s)-3-methylpiperazine-1-carboxylate Chemical compound C[C@H]1CN(C(=O)OC(C)(C)C)CCN1 FMLPQHJYUZTHQS-QMMMGPOBSA-N 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- LKDJYZBKCVSODK-OLQVQODUSA-N (1s,5r)-3,8-diazabicyclo[3.2.1]octane Chemical compound C1NC[C@@H]2CC[C@H]1N2 LKDJYZBKCVSODK-OLQVQODUSA-N 0.000 description 1
- CLGIPVVEERQWSQ-UHFFFAOYSA-N (2,3,4-trifluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C(F)=C1F CLGIPVVEERQWSQ-UHFFFAOYSA-N 0.000 description 1
- DBZAICSEFBVFHL-UHFFFAOYSA-N (2,6-difluorophenyl)boronic acid Chemical compound OB(O)C1=C(F)C=CC=C1F DBZAICSEFBVFHL-UHFFFAOYSA-N 0.000 description 1
- XOVMDVZAWWQSDC-UHFFFAOYSA-N (2-fluoro-6-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(F)=C1B(O)O XOVMDVZAWWQSDC-UHFFFAOYSA-N 0.000 description 1
- DWSBPCLAELVSFD-UHFFFAOYSA-N (2-fluorophenoxy)boronic acid Chemical compound OB(O)OC1=CC=CC=C1F DWSBPCLAELVSFD-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- MVWFPRWHZFBWSY-NTSWFWBYSA-N (2r,5s)-2,5-dimethylpiperazine-1-carboxylic acid Chemical compound C[C@H]1CN(C(O)=O)[C@H](C)CN1 MVWFPRWHZFBWSY-NTSWFWBYSA-N 0.000 description 1
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- CRYXXTXWUCPIMU-WNQIDUERSA-N (2s)-2-aminobutanediamide;phenol Chemical compound OC1=CC=CC=C1.NC(=O)[C@@H](N)CC(N)=O CRYXXTXWUCPIMU-WNQIDUERSA-N 0.000 description 1
- ABTBKKHOMBEJGL-UHFFFAOYSA-N (3-fluoro-2-methoxyphenyl)boronic acid Chemical compound COC1=C(F)C=CC=C1B(O)O ABTBKKHOMBEJGL-UHFFFAOYSA-N 0.000 description 1
- NYBIUWJUWTUGFV-UHFFFAOYSA-N (3-fluoro-2-methylphenyl)boronic acid Chemical compound CC1=C(F)C=CC=C1B(O)O NYBIUWJUWTUGFV-UHFFFAOYSA-N 0.000 description 1
- ADJBXDCXYMCCAD-UHFFFAOYSA-N (4-fluoro-2-methoxyphenyl)boronic acid Chemical compound COC1=CC(F)=CC=C1B(O)O ADJBXDCXYMCCAD-UHFFFAOYSA-N 0.000 description 1
- HRURFOBSNYPWDM-UHFFFAOYSA-N (5-methyl-1h-indazol-4-yl)boronic acid Chemical compound CC1=CC=C2NN=CC2=C1B(O)O HRURFOBSNYPWDM-UHFFFAOYSA-N 0.000 description 1
- FGZCRPIUNHHXMV-UHFFFAOYSA-N (8-methylnaphthalen-1-yl)boronic acid Chemical compound C1=CC(B(O)O)=C2C(C)=CC=CC2=C1 FGZCRPIUNHHXMV-UHFFFAOYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- QFCMBRXRVQRSSF-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropyrrolo[3,4-c]pyrrole Chemical compound C1NCC2CNCC21 QFCMBRXRVQRSSF-UHFFFAOYSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- FBNAMBTYMSWTIB-UHFFFAOYSA-N 1,3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound CC1=NN(C)C=C1B1OC(C)(C)C(C)(C)O1 FBNAMBTYMSWTIB-UHFFFAOYSA-N 0.000 description 1
- WYLZKEAKTKRGKT-UHFFFAOYSA-N 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-one Chemical compound CN1C(=O)C(C)=CC(B2OC(C)(C)C(C)(C)O2)=C1 WYLZKEAKTKRGKT-UHFFFAOYSA-N 0.000 description 1
- QUGUFLJIAFISSW-UHFFFAOYSA-N 1,4-difluorobenzene Chemical compound FC1=CC=C(F)C=C1 QUGUFLJIAFISSW-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- XMJRZCYSCMZVJQ-UHFFFAOYSA-N 2,5,6-trichloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC(Cl)=C(Cl)N=C1Cl XMJRZCYSCMZVJQ-UHFFFAOYSA-N 0.000 description 1
- UDSAJFSYJMHNFI-UHFFFAOYSA-N 2,6-diazaspiro[3.3]heptane Chemical compound C1NCC11CNC1 UDSAJFSYJMHNFI-UHFFFAOYSA-N 0.000 description 1
- DROZYMFJWSYDRY-UHFFFAOYSA-N 2,7-diazaspiro[3.5]nonane Chemical compound C1NCC11CCNCC1 DROZYMFJWSYDRY-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- TYCFGHUTYSLISP-UHFFFAOYSA-N 2-fluoroprop-2-enoic acid Chemical compound OC(=O)C(F)=C TYCFGHUTYSLISP-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- FSJAKASJCJZKET-UHFFFAOYSA-N 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CN=C1N FSJAKASJCJZKET-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- VFLACVCBRRFRNU-UHFFFAOYSA-N 4,6-dichloro-7-(2-fluoro-3-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2-one Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1C)=C1F)C(Cl)=C1)=C1C(Cl)=N1)C1=O VFLACVCBRRFRNU-UHFFFAOYSA-N 0.000 description 1
- FDBTUNPAIITAPT-UHFFFAOYSA-N 4-(2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-yl)-7-(2-methoxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1)=C1OC)C(C#N)=C1)=C1C(N1CC(CNC2)C2C1)=N1)C1=O FDBTUNPAIITAPT-UHFFFAOYSA-N 0.000 description 1
- SDBQUCBJFCSMMW-UHFFFAOYSA-N 4-(2,5-diazabicyclo[2.2.2]octan-2-yl)-7-(2-fluoro-5-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=C(C)C=C1)=C1F)C(C#N)=C1)=C1C(N1C(CC2)CNC2C1)=N1)C1=O SDBQUCBJFCSMMW-UHFFFAOYSA-N 0.000 description 1
- BXFVZKNQGAWPPM-UHFFFAOYSA-N 4-(2,6-diazaspiro[3.3]heptan-2-yl)-7-(2-methoxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1)=C1OC)C(C#N)=C1)=C1C(N1CC2(CNC2)C1)=N1)C1=O BXFVZKNQGAWPPM-UHFFFAOYSA-N 0.000 description 1
- KEMHIDITMOFQLW-UHFFFAOYSA-N 4-(2,6-dimethyl-4-prop-2-enoylpiperazin-1-yl)-7-(2-fluoro-5-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=C(C)C=C1)=C1F)C(C#N)=C1)=C1C(N(C(C)C1)C(C)CN1C(C=C)=O)=N1)C1=O KEMHIDITMOFQLW-UHFFFAOYSA-N 0.000 description 1
- FQJSBAXPFAGRIT-UHFFFAOYSA-N 4-(2,7-diazaspiro[3.5]nonan-7-yl)-7-(2-methoxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1)=C1OC)C(C#N)=C1)=C1C(N1CCC2(CNC2)CC1)=N1)C1=O FQJSBAXPFAGRIT-UHFFFAOYSA-N 0.000 description 1
- HSJWQMNOFQFCLZ-UHFFFAOYSA-N 4-(2,7-diazaspiro[4.4]nonan-2-yl)-7-(2-methoxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1)=C1OC)C(C#N)=C1)=C1C(N(CC1)CC11CNCC1)=N1)C1=O HSJWQMNOFQFCLZ-UHFFFAOYSA-N 0.000 description 1
- BBBNUFIAOHPNTP-UHFFFAOYSA-N 4-(4,7-diazaspiro[2.5]octan-4-yl)-7-(2-methoxy-3-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1C)=C1OC)C(C#N)=C1)=C1C(N1C2(CC2)CNCC1)=N1)C1=O BBBNUFIAOHPNTP-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- HPKNJELBBXYJCZ-YADHBBJMSA-N 4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-7-(2-fluoro-3-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1C)=C1F)C(C#N)=C1)=C1C(N(C[C@H]1C)[C@@H](C)CN1C(C=C)=O)=N1)C1=O HPKNJELBBXYJCZ-YADHBBJMSA-N 0.000 description 1
- DPZXPRKLSRXJHJ-PKTZIBPZSA-N 4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-7-(2-fluoro-5-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxoquinazoline-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(C(C(N(C[C@H]1C)[C@@H](C)CN1C(C=C)=O)=N1)=C2)=CC(C(C=C(C)C=C3)=C3F)=C2C#N)C1=O DPZXPRKLSRXJHJ-PKTZIBPZSA-N 0.000 description 1
- VKFGAQPZQUQHSX-UXHICEINSA-N 4-[(2S,5R)-2,5-dimethylpiperazin-1-yl]-7-(2-fluoro-3-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1C)=C1F)C(C#N)=C1)=C1C(N1[C@@H](C)CN[C@H](C)C1)=N1)C1=O VKFGAQPZQUQHSX-UXHICEINSA-N 0.000 description 1
- XLDBAUICWKLZLM-UXHICEINSA-N 4-[(2S,5R)-2,5-dimethylpiperazin-1-yl]-7-(2-fluoro-5-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=C(C)C=C1)=C1F)C(C#N)=C1)=C1C(N1[C@@H](C)CN[C@H](C)C1)=N1)C1=O XLDBAUICWKLZLM-UXHICEINSA-N 0.000 description 1
- LADJGNQLDNIPOJ-RTWAWAEBSA-N 4-[(2S,5R)-2,5-dimethylpiperazin-1-yl]-7-(2-fluoro-5-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxoquinazoline-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(C(C(N1[C@@H](C)CN[C@H](C)C1)=N1)=C2)=CC(C(C=C(C)C=C3)=C3F)=C2C#N)C1=O LADJGNQLDNIPOJ-RTWAWAEBSA-N 0.000 description 1
- KEMHIDITMOFQLW-SZPZYZBQSA-N 4-[(2S,6R)-2,6-dimethyl-4-prop-2-enoylpiperazin-1-yl]-7-(2-fluoro-5-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=C(C)C=C1)=C1F)C(C#N)=C1)=C1C(N([C@H](C)C1)[C@@H](C)CN1C(C=C)=O)=N1)C1=O KEMHIDITMOFQLW-SZPZYZBQSA-N 0.000 description 1
- IVIPOIMJHIOYFX-BGYRXZFFSA-N 4-[(2S,6R)-2,6-dimethylpiperazin-1-yl]-7-(2-fluoro-5-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=C(C)C=C1)=C1F)C(C#N)=C1)=C1C(N1[C@@H](C)CNC[C@H]1C)=N1)C1=O IVIPOIMJHIOYFX-BGYRXZFFSA-N 0.000 description 1
- POILWHVDKZOXJZ-UHFFFAOYSA-N 4-hydroxypent-3-en-2-one Chemical compound CC(O)=CC(C)=O POILWHVDKZOXJZ-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- HXPMRPRBABWPKL-UHFFFAOYSA-N 5-bromo-3-methyl-1h-pyridin-2-one Chemical compound CC1=CC(Br)=CN=C1O HXPMRPRBABWPKL-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- TXRJRLWXGWIRKP-UHFFFAOYSA-N 6,7-dichloro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4-dione Chemical compound ClC1=CC2=C(N(C(NC2=O)=O)C=2C(=NC=CC=2C)C(C)C)N=C1Cl TXRJRLWXGWIRKP-UHFFFAOYSA-N 0.000 description 1
- JLGRZEWGCKOJRU-UHFFFAOYSA-N 6-chloro-7-(2-fluoro-3-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4-dione Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1C)=C1F)C(Cl)=C1)=C1C(N1)=O)C1=O JLGRZEWGCKOJRU-UHFFFAOYSA-N 0.000 description 1
- YEESZQPENKWHKY-NRFANRHFSA-N 7-(1,5-dimethyl-6-oxopyridin-3-yl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=C1C)=CN(C)C1=O)C(C#N)=C1)=C1C(N(CC1)[C@@H](C)CN1C(C=C)=O)=N1)C1=O YEESZQPENKWHKY-NRFANRHFSA-N 0.000 description 1
- CHXWYFQVXHHEFD-IBGZPJMESA-N 7-(2,5-difluorophenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=C(C=C1)F)=C1F)C(C#N)=C1)=C1C(N(CC1)[C@@H](C)CN1C(C=C)=O)=N1)C1=O CHXWYFQVXHHEFD-IBGZPJMESA-N 0.000 description 1
- FEFBDTIZSLITSZ-IBGZPJMESA-N 7-(2,6-difluorophenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C#N)=C1)C(C(F)=CC=C2)=C2F)=C1C(N(CC1)[C@@H](C)CN1C(C=C)=O)=N1)C1=O FEFBDTIZSLITSZ-IBGZPJMESA-N 0.000 description 1
- UWYXEFFJYKPYNC-UXHICEINSA-N 7-(2-aminopyridin-3-yl)-4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C1=CC=CN=C1N)C(C#N)=C1)=C1C(N(C[C@H]1C)[C@@H](C)CN1C(C=C)=O)=N1)C1=O UWYXEFFJYKPYNC-UXHICEINSA-N 0.000 description 1
- JUHSSVJLUIYJHW-UHFFFAOYSA-N 7-(2-fluoro-5-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxo-4-(5-prop-2-enoyl-2,5-diazabicyclo[2.2.2]octan-2-yl)pyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=C(C)C=C1)=C1F)C(C#N)=C1)=C1C(N(CC1CC2)C2CN1C(C=C)=O)=N1)C1=O JUHSSVJLUIYJHW-UHFFFAOYSA-N 0.000 description 1
- LEXQESAUROWTGR-SFHVURJKSA-N 7-(2-fluoro-6-methoxyphenyl)-4-[(2S)-2-methylpiperazin-1-yl]-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C#N)=C1)C(C(OC)=CC=C2)=C2F)=C1C(N1[C@@H](C)CNCC1)=N1)C1=O LEXQESAUROWTGR-SFHVURJKSA-N 0.000 description 1
- HIBTUWKZPJXGEQ-UHFFFAOYSA-N 7-(2-fluorophenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxo-4-(7-prop-2-enoyl-4,7-diazaspiro[2.5]octan-4-yl)pyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1)=C1F)C(C#N)=C1)=C1C(N(CC1)C2(CC2)CN1C(C=C)=O)=N1)C1=O HIBTUWKZPJXGEQ-UHFFFAOYSA-N 0.000 description 1
- KZJRVDWJNMWREI-UHFFFAOYSA-N 7-(2-methoxy-3-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxo-4-(7-prop-2-enoyl-4,7-diazaspiro[2.5]octan-4-yl)pyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1C)=C1OC)C(C#N)=C1)=C1C(N(CC1)C2(CC2)CN1C(C=C)=O)=N1)C1=O KZJRVDWJNMWREI-UHFFFAOYSA-N 0.000 description 1
- NRUUEJMRQQLUPS-QFIPXVFZSA-N 7-(2-methoxy-3-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1C)=C1OC)C(C#N)=C1)=C1C(N(CC1)[C@@H](C)CN1C(C=C)=O)=N1)C1=O NRUUEJMRQQLUPS-QFIPXVFZSA-N 0.000 description 1
- LXMBUTIMWUDTOH-UHFFFAOYSA-N 7-(2-methoxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxo-4-(2-prop-2-enoyl-2,6-diazaspiro[3.3]heptan-6-yl)pyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1)=C1OC)C(C#N)=C1)=C1C(N1CC(C2)(CN2C(C=C)=O)C1)=N1)C1=O LXMBUTIMWUDTOH-UHFFFAOYSA-N 0.000 description 1
- FCHHGRGBQKMXHB-UHFFFAOYSA-N 7-(2-methoxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxo-4-(2-prop-2-enoyl-2,7-diazaspiro[3.5]nonan-7-yl)pyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1)=C1OC)C(C#N)=C1)=C1C(N1CCC(C2)(CN2C(C=C)=O)CC1)=N1)C1=O FCHHGRGBQKMXHB-UHFFFAOYSA-N 0.000 description 1
- AVVMQBVNMBVFGU-UHFFFAOYSA-N 7-(2-methoxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxo-4-(5-prop-2-enoyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2-yl)pyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1)=C1OC)C(C#N)=C1)=C1C(N1CC(CN(C2)C(C=C)=O)C2C1)=N1)C1=O AVVMQBVNMBVFGU-UHFFFAOYSA-N 0.000 description 1
- DYTZGDKHECUZFY-NRFANRHFSA-N 7-(2-methoxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1)=C1OC)C(C#N)=C1)=C1C(N(CC1)[C@@H](C)CN1C(C=C)=O)=N1)C1=O DYTZGDKHECUZFY-NRFANRHFSA-N 0.000 description 1
- RTHUEHAQCDDHCU-IBGZPJMESA-N 7-(2-methoxyphenyl)-4-[(2S)-2-methylpiperazin-1-yl]-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1)=C1OC)C(C#N)=C1)=C1C(N1[C@@H](C)CNCC1)=N1)C1=O RTHUEHAQCDDHCU-IBGZPJMESA-N 0.000 description 1
- DDUQGQSGAFTVRA-NRFANRHFSA-N 7-(5-methyl-1H-indazol-4-yl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C#N)=C1)C2=C(C=NN3)C3=CC=C2C)=C1C(N(CC1)[C@@H](C)CN1C(C=C)=O)=N1)C1=O DDUQGQSGAFTVRA-NRFANRHFSA-N 0.000 description 1
- PSCDTXMQHMQKPV-YADHBBJMSA-N 7-(cyclohexen-1-yl)-4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C1=CCCCC1)C(C#N)=C1)=C1C(N(C[C@H]1C)[C@@H](C)CN1C(C=C)=O)=N1)C1=O PSCDTXMQHMQKPV-YADHBBJMSA-N 0.000 description 1
- COPGTPBILLYUPQ-UXHICEINSA-N 7-(cyclohexen-1-yl)-4-[(2S,5R)-2,5-dimethylpiperazin-1-yl]-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C1=CCCCC1)C(C#N)=C1)=C1C(N1[C@@H](C)CN[C@H](C)C1)=N1)C1=O COPGTPBILLYUPQ-UXHICEINSA-N 0.000 description 1
- XYNHBJBYHJJYQL-YADHBBJMSA-N 7-cyclohexyl-4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C1CCCCC1)C(C#N)=C1)=C1C(N(C[C@H]1C)[C@@H](C)CN1C(C=C)=O)=N1)C1=O XYNHBJBYHJJYQL-YADHBBJMSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- AQLLBJAXUCIJSR-UHFFFAOYSA-N OC(=O)C[Na] Chemical compound OC(=O)C[Na] AQLLBJAXUCIJSR-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- BVXVOVZHMQFVFB-UHFFFAOYSA-M [C-]#N.[Zn+2].[Cl-] Chemical compound [C-]#N.[Zn+2].[Cl-] BVXVOVZHMQFVFB-UHFFFAOYSA-M 0.000 description 1
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 1
- WJEIYVAPNMUNIU-UHFFFAOYSA-N [Na].OC(O)=O Chemical compound [Na].OC(O)=O WJEIYVAPNMUNIU-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000015961 delipidation Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- BLNWTAHYTCHDJH-UHFFFAOYSA-O hydroxy(oxo)azanium Chemical compound O[NH+]=O BLNWTAHYTCHDJH-UHFFFAOYSA-O 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940125399 kras g12c inhibitor Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- PJEOKPLETLYNSV-FQEVSTJZSA-N methyl 3-[6-cyano-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]-2-oxopyrido[2,3-d]pyrimidin-7-yl]-4-fluorobenzoate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=C(C=C1)C(OC)=O)=C1F)C(C#N)=C1)=C1C(N(CC1)[C@@H](C)CN1C(C=C)=O)=N1)C1=O PJEOKPLETLYNSV-FQEVSTJZSA-N 0.000 description 1
- BPAKMNNACPYTAY-UHFFFAOYSA-N methyl 4-amino-2-fluorobenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1F BPAKMNNACPYTAY-UHFFFAOYSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical compound O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- PSDAEKDIOQXLLC-DTORHVGOSA-N tert-butyl (1r,5s)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)C[C@@]2([H])CC[C@]1([H])N2 PSDAEKDIOQXLLC-DTORHVGOSA-N 0.000 description 1
- YILADXAJTZSFJO-BJKOFHAPSA-N tert-butyl (2R,5S)-4-[6-cyano-7-(2-fluoro-5-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxoquinazolin-4-yl]-2,5-dimethylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(C(C(N(C[C@H]1C)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)=C2)=CC(C(C=C(C)C=C3)=C3F)=C2C#N)C1=O YILADXAJTZSFJO-BJKOFHAPSA-N 0.000 description 1
- RDUMOYBGWOKFGT-BJKOFHAPSA-N tert-butyl (2R,5S)-4-[6-cyano-7-(2-methoxy-3-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-2,5-dimethylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1C)=C1OC)C(C#N)=C1)=C1C(N(C[C@H]1C)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)C1=O RDUMOYBGWOKFGT-BJKOFHAPSA-N 0.000 description 1
- KRHCEZCUSPEHJK-XZOQPEGZSA-N tert-butyl (2R,5S)-4-[6-cyano-7-(cyclohexen-1-yl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-2,5-dimethylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C1=CCCCC1)C(C#N)=C1)=C1C(N(C[C@H]1C)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)C1=O KRHCEZCUSPEHJK-XZOQPEGZSA-N 0.000 description 1
- GDGPDJNPFCKMJH-XZOQPEGZSA-N tert-butyl (2R,5S)-4-[6-cyano-7-cyclohexyl-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-2,5-dimethylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C1CCCCC1)C(C#N)=C1)=C1C(N(C[C@H]1C)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)C1=O GDGPDJNPFCKMJH-XZOQPEGZSA-N 0.000 description 1
- FZTLVNBOIJVMMY-CALCHBBNSA-N tert-butyl (3R,5S)-4-[6,7-dichloro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-3,5-dimethylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(Cl)=C1)Cl)=C1C(N([C@H](C)C1)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)C1=O FZTLVNBOIJVMMY-CALCHBBNSA-N 0.000 description 1
- AHYKGKMSHGZSLL-INIZCTEOSA-N tert-butyl (3S)-4-[6-bromo-7-iodo-1-(2-methyl-4-propan-2-ylpyridin-3-yl)-2-oxoquinazolin-4-yl]-3-methylpiperazine-1-carboxylate Chemical compound CC(C)C(C=CN=C1C)=C1N(C(C(C(N(CC1)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)=C2)=CC(I)=C2Br)C1=O AHYKGKMSHGZSLL-INIZCTEOSA-N 0.000 description 1
- ARPOVZPWJYRYPY-SFHVURJKSA-N tert-butyl (3S)-4-[6-chloro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxo-7-(2,3,4-trifluorophenyl)pyrido[2,3-d]pyrimidin-4-yl]-3-methylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC(F)=C1F)=C1F)C(Cl)=C1)=C1C(N(CC1)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)C1=O ARPOVZPWJYRYPY-SFHVURJKSA-N 0.000 description 1
- OVYWAQVEPSRDAE-IBGZPJMESA-N tert-butyl (3S)-4-[6-chloro-7-(2,5-difluorophenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-3-methylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=C(C=C1)F)=C1F)C(Cl)=C1)=C1C(N(CC1)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)C1=O OVYWAQVEPSRDAE-IBGZPJMESA-N 0.000 description 1
- SAKXFEHMRLTUNB-NRFANRHFSA-N tert-butyl (3S)-4-[6-chloro-7-(2-fluoro-5-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-3-methylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=C(C)C=C1)=C1F)C(Cl)=C1)=C1C(N(CC1)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)C1=O SAKXFEHMRLTUNB-NRFANRHFSA-N 0.000 description 1
- PMAMHMAXHQQRJL-NRFANRHFSA-N tert-butyl (3S)-4-[6-chloro-7-(2-methoxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-3-methylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1)=C1OC)C(Cl)=C1)=C1C(N(CC1)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)C1=O PMAMHMAXHQQRJL-NRFANRHFSA-N 0.000 description 1
- QDMNDBQRKNVGCE-FQEVSTJZSA-N tert-butyl (3S)-4-[6-chloro-7-(3-fluoro-2-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-3-methylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C1=C(C)C(F)=CC=C1)C(Cl)=C1)=C1C(N(CC1)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)C1=O QDMNDBQRKNVGCE-FQEVSTJZSA-N 0.000 description 1
- WOODJWPPIZUEOS-NRFANRHFSA-N tert-butyl (3S)-4-[6-chloro-7-(5-methyl-1H-indazol-4-yl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-3-methylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(Cl)=C1)C2=C(C=NN3)C3=CC=C2C)=C1C(N(CC1)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)C1=O WOODJWPPIZUEOS-NRFANRHFSA-N 0.000 description 1
- YDSBONUYTMSWSN-DEOSSOPVSA-N tert-butyl (3S)-4-[6-chloro-7-(8-methylnaphthalen-1-yl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-3-methylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C1=CC=CC2=CC=CC(C)=C12)C(Cl)=C1)=C1C(N(CC1)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)C1=O YDSBONUYTMSWSN-DEOSSOPVSA-N 0.000 description 1
- ONRJYNWSRWQWJP-FQEVSTJZSA-N tert-butyl (3S)-4-[6-cyano-7-(2,5-difluorophenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-3-methylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=C(C=C1)F)=C1F)C(C#N)=C1)=C1C(N(CC1)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)C1=O ONRJYNWSRWQWJP-FQEVSTJZSA-N 0.000 description 1
- DQICECJOYYDESZ-FQEVSTJZSA-N tert-butyl (3S)-4-[6-cyano-7-(2,6-difluorophenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-3-methylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C#N)=C1)C(C(F)=CC=C2)=C2F)=C1C(N(CC1)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)C1=O DQICECJOYYDESZ-FQEVSTJZSA-N 0.000 description 1
- AVPXETUZVILSOS-NRFANRHFSA-N tert-butyl (3S)-4-[6-cyano-7-(2-fluoro-6-methoxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-3-methylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C#N)=C1)C(C(OC)=CC=C2)=C2F)=C1C(N(CC1)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)C1=O AVPXETUZVILSOS-NRFANRHFSA-N 0.000 description 1
- NXRGNGJQNXNHOO-QFIPXVFZSA-N tert-butyl (3S)-4-[6-cyano-7-(5-methyl-1H-indazol-4-yl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-3-methylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C#N)=C1)C2=C(C=NN3)C3=CC=C2C)=C1C(N(CC1)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)C1=O NXRGNGJQNXNHOO-QFIPXVFZSA-N 0.000 description 1
- NUZXPHIQZUYMOR-DTORHVGOSA-N tert-butyl (3s,5r)-3,5-dimethylpiperazine-1-carboxylate Chemical compound C[C@H]1CN(C(=O)OC(C)(C)C)C[C@@H](C)N1 NUZXPHIQZUYMOR-DTORHVGOSA-N 0.000 description 1
- FYUVLZRRIRGSTE-UHFFFAOYSA-N tert-butyl 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrole-5-carboxylate Chemical compound C1NCC2CN(C(=O)OC(C)(C)C)CC21 FYUVLZRRIRGSTE-UHFFFAOYSA-N 0.000 description 1
- RBLOMFQUEUBEBG-UHFFFAOYSA-N tert-butyl 2,5-diazabicyclo[2.2.2]octane-2-carboxylate Chemical compound C1CC2N(C(=O)OC(C)(C)C)CC1NC2 RBLOMFQUEUBEBG-UHFFFAOYSA-N 0.000 description 1
- KVOUHLVOTMOJBS-UHFFFAOYSA-N tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC11CNC1 KVOUHLVOTMOJBS-UHFFFAOYSA-N 0.000 description 1
- HWLNKJXLGQVMJH-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[3.5]nonane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC21CCNCC2 HWLNKJXLGQVMJH-UHFFFAOYSA-N 0.000 description 1
- HPPARSNAMZJAPZ-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.4]nonane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC11CNCC1 HPPARSNAMZJAPZ-UHFFFAOYSA-N 0.000 description 1
- PNBDWXZYIZDZQY-UHFFFAOYSA-N tert-butyl 2-[6-chloro-7-(2-methoxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1)=C1OC)C(Cl)=C1)=C1C(N1CC(CN(C2)C(OC(C)(C)C)=O)C2C1)=N1)C1=O PNBDWXZYIZDZQY-UHFFFAOYSA-N 0.000 description 1
- WDAILNYUZCVABD-UHFFFAOYSA-N tert-butyl 2-[6-cyano-7-(2-methoxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1)=C1OC)C(C#N)=C1)=C1C(N1CC(CN(C2)C(OC(C)(C)C)=O)C2C1)=N1)C1=O WDAILNYUZCVABD-UHFFFAOYSA-N 0.000 description 1
- NUZXPHIQZUYMOR-UHFFFAOYSA-N tert-butyl 3,5-dimethylpiperazine-1-carboxylate Chemical compound CC1CN(C(=O)OC(C)(C)C)CC(C)N1 NUZXPHIQZUYMOR-UHFFFAOYSA-N 0.000 description 1
- XXKCYKIJWLFVDG-UHFFFAOYSA-N tert-butyl 4,7-diazaspiro[2.5]octane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCNC11CC1 XXKCYKIJWLFVDG-UHFFFAOYSA-N 0.000 description 1
- FZTLVNBOIJVMMY-UHFFFAOYSA-N tert-butyl 4-[6,7-dichloro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-3,5-dimethylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(Cl)=C1)Cl)=C1C(N(C(C)C1)C(C)CN1C(OC(C)(C)C)=O)=N1)C1=O FZTLVNBOIJVMMY-UHFFFAOYSA-N 0.000 description 1
- OZEWXZYNMWKIBP-UHFFFAOYSA-N tert-butyl 4-[6-chloro-7-(2-fluoro-5-methylphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-3,5-dimethylpiperazine-1-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=C(C)C=C1)=C1F)C(Cl)=C1)=C1C(N(C(C)C1)C(C)CN1C(OC(C)(C)C)=O)=N1)C1=O OZEWXZYNMWKIBP-UHFFFAOYSA-N 0.000 description 1
- LLYAZLYWJYJFJD-UHFFFAOYSA-N tert-butyl 5-[6,7-dichloro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-2,5-diazabicyclo[2.2.2]octane-2-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(Cl)=C1)Cl)=C1C(N(CC1CC2)C2CN1C(OC(C)(C)C)=O)=N1)C1=O LLYAZLYWJYJFJD-UHFFFAOYSA-N 0.000 description 1
- YUAHSJJTBBKDTR-UHFFFAOYSA-N tert-butyl 6-[6,7-dichloro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-2,6-diazaspiro[3.3]heptane-2-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(Cl)=C1)Cl)=C1C(N1CC(C2)(CN2C(OC(C)(C)C)=O)C1)=N1)C1=O YUAHSJJTBBKDTR-UHFFFAOYSA-N 0.000 description 1
- LBUGEKCWEZJFQK-UHFFFAOYSA-N tert-butyl 6-[6-chloro-7-(2-methoxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-2,6-diazaspiro[3.3]heptane-2-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1)=C1OC)C(Cl)=C1)=C1C(N1CC(C2)(CN2C(OC(C)(C)C)=O)C1)=N1)C1=O LBUGEKCWEZJFQK-UHFFFAOYSA-N 0.000 description 1
- OAUMWJQXZLHGBJ-UHFFFAOYSA-N tert-butyl 6-[6-cyano-7-(2-methoxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-2,6-diazaspiro[3.3]heptane-2-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1)=C1OC)C(C#N)=C1)=C1C(N1CC(C2)(CN2C(OC(C)(C)C)=O)C1)=N1)C1=O OAUMWJQXZLHGBJ-UHFFFAOYSA-N 0.000 description 1
- NGWLGEHEIPAVKC-UHFFFAOYSA-N tert-butyl 7-[6,7-dichloro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-2,7-diazaspiro[3.5]nonane-2-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(Cl)=C1)Cl)=C1C(N1CCC(C2)(CN2C(OC(C)(C)C)=O)CC1)=N1)C1=O NGWLGEHEIPAVKC-UHFFFAOYSA-N 0.000 description 1
- XACNVRVQHTVOSK-UHFFFAOYSA-N tert-butyl 7-[6,7-dichloro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-2,7-diazaspiro[4.4]nonane-2-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(Cl)=C1)Cl)=C1C(N(CC1)CC1(CC1)CN1C(OC(C)(C)C)=O)=N1)C1=O XACNVRVQHTVOSK-UHFFFAOYSA-N 0.000 description 1
- HDABNSAAAFORDZ-UHFFFAOYSA-N tert-butyl 7-[6-chloro-7-(2-methoxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-2,7-diazaspiro[3.5]nonane-2-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1)=C1OC)C(Cl)=C1)=C1C(N1CCC(C2)(CN2C(OC(C)(C)C)=O)CC1)=N1)C1=O HDABNSAAAFORDZ-UHFFFAOYSA-N 0.000 description 1
- BDJVFWRLMSBOJR-UHFFFAOYSA-N tert-butyl 7-[6-chloro-7-(2-methoxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-2,7-diazaspiro[4.4]nonane-2-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1)=C1OC)C(Cl)=C1)=C1C(N(CC1)CC1(CC1)CN1C(OC(C)(C)C)=O)=N1)C1=O BDJVFWRLMSBOJR-UHFFFAOYSA-N 0.000 description 1
- HKXBPVMBQUQZLC-UHFFFAOYSA-N tert-butyl 7-[6-cyano-7-(2-methoxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-2,7-diazaspiro[3.5]nonane-2-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1)=C1OC)C(C#N)=C1)=C1C(N1CCC(C2)(CN2C(OC(C)(C)C)=O)CC1)=N1)C1=O HKXBPVMBQUQZLC-UHFFFAOYSA-N 0.000 description 1
- UDCUWJHHEQVWDN-UHFFFAOYSA-N tert-butyl 7-[6-cyano-7-(2-methoxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-2,7-diazaspiro[4.4]nonane-2-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(C=CC=C1)=C1OC)C(C#N)=C1)=C1C(N(CC1)CC1(CC1)CN1C(OC(C)(C)C)=O)=N1)C1=O UDCUWJHHEQVWDN-UHFFFAOYSA-N 0.000 description 1
- SBBDUTVXFNQXMY-UHFFFAOYSA-N tert-butyl 8-[6,7-dichloro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxopyrido[2,3-d]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylate Chemical compound CC(C)C1=NC=CC(C)=C1N(C(N=C(C(Cl)=C1)Cl)=C1C(N(C(CC1)C2)C1CN2C(OC(C)(C)C)=O)=N1)C1=O SBBDUTVXFNQXMY-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000005503 thioxanyl group Chemical group 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the invention belongs to the field of medicine, and specifically relates to a new class of compounds as KRAS activity inhibitors, a method for preparing them, a pharmaceutical composition comprising the compound, and the application of the compound and the pharmaceutical composition in the treatment of various diseases . More specifically, the compounds described in the present invention can act as inhibitors of the activity or function of KRAS G12C.
- KRAS is a murine sarcoma virus gene.
- the KRAS gene encodes a 21kD ras protein, also known as the p21 gene.
- RAS the ras gene family associated with human tumors
- KRAS has the greatest impact on human cancers, accounting for 86% of all RAS mutations. It acts like a molecular switch: when normal, it controls the pathway that regulates cell growth; when abnormal, it causes cells to continue growing and stops them self-destruction. It is involved in intracellular signal transmission.
- the K-ras gene is mutated, the gene is permanently activated and normal ras protein cannot be produced, resulting in disordered intracellular signal transduction, uncontrolled cell proliferation and canceration.
- KRAS G12C mutation is a relatively common subtype of KRAS gene mutation, which refers to the mutation of glycine No. 12 to cysteine.
- KRAS G12C mutation is the most common in lung cancer. According to the data reported in the literature (Nat Rev Drug Discov 2014; 13:828-851), KRAS G12C mutation accounts for about 10% of all lung cancer patients.
- the present invention provides a compound, or a pharmaceutical composition thereof, which acts as an inhibitor of KRAS.
- the present invention further relates to the use of the compound or a pharmaceutical composition thereof for the manufacture of a medicament for the treatment of a disease and/or disorder by inhibiting the activity of KRAS by the compound.
- the present invention further describes the synthesis of said compounds.
- the compounds of the present invention exhibit excellent biological activity and pharmacokinetic properties.
- the present invention relates to a compound, which is a compound represented by formula (I), or a stereoisomer, geometric isomer, tautomer, nitroxide of a compound represented by formula (I) compounds, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs,
- X is -LX 1 -, wherein L is a bond or NH, X 1 is a 4-8-membered monocyclic ring, 5-12-membered condensed ring, 5-12-membered spirocyclic ring or 5-12-membered bridged ring containing nitrogen atoms,
- the 4-8-membered monocyclic ring, 5-12-membered fused ring, 5-12-membered spiro ring and 5-12-membered bridged ring can be independently optionally substituted with m R x ;
- Y is N or CH
- Z is N or CR 2e ;
- R a and R b are each independently hydrogen, deuterium, halogen atom, C 1-3 alkyl, C 1-3 haloalkyl or C 1-3 alkoxy, wherein the C 1-3 alkyl, C 1-3 haloalkyl and C 1-3 alkoxy independently optionally by 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxo, amino, nitro, cyano , C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 haloalkoxy and C 1-3 hydroxyalkoxy groups;
- R c is hydrogen, deuterium, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy , C 1-6 alkylamino, 5-6-membered heteroaryl, C 3-6 carbocyclic or 3-6-membered heterocyclic, wherein the C 1-6 alkyl, C 2-6 alkenyl , C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkylamino, 5-6 membered heteroaryl, C 3-6 Carbocyclyl and 3-6 membered heterocyclyl are independently optionally substituted by 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxo, amino, nitro, cyano, C1 -3 alkyl, C 1-3 haloalkyl, C 1-3
- R 3 is C 6-12 aryl or 5-10-membered heteroaryl, wherein the C 6-12 aryl and 5-10-membered heteroaryl are independently optionally substituted by n R y ;
- R 2a , R 2b , R 2c , R 2d and R 2e are each independently hydrogen, deuterium, fluorine, chlorine, bromine, iodine, hydroxy, amino, nitro, cyano, C 1-6 alkyl, C 2- 6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy or C 1-6 alkylamino; wherein, the C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy and C 1-6 alkylamino independently optionally by 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxo, amino, nitro, cyano, C 1-3 alkyl, C 1-3 haloalkyl, C 1- 3 alkoxy, C 1-3 haloalkoxy and
- Each R x is independently deuterium, fluorine, chlorine, bromine, iodine, hydroxy, oxo, amino, nitro, cyano, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkylamino, C 3-8 cycloalkyl or 3-8 membered heterocyclic group; wherein, the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkoxy Amino, C 3-8 cycloalkyl and 3-8 membered heterocyclyl are independently optionally 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxo, amino, nitro , cyano, C 1-3 alkyl, C
- n 0, 1, 2, 3, 4, 5, 6, 7 or 8;
- n 1, 2, 3, 4, 5, 6 or 7.
- X is Wherein, the m and R x have the meanings described in the present invention.
- R and R are each independently hydrogen, deuterium , halogen, methyl, ethyl, n -propyl, isopropyl, trifluoromethyl, difluoromethyl, methoxy, Ethoxy or isopropoxy, wherein said methyl, ethyl, n-propyl, isopropyl, difluoromethyl, methoxy, ethoxy and isopropoxy are independently optionally 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxo, amino, nitro, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl , difluoromethyl, methoxy, ethoxy, isopropoxy, trifluoromethoxy, -OCH 2 OH and -OCH 2 CH 2 OH groups;
- R c is hydrogen, deuterium, methyl, ethyl, n-propyl, isopropyl, allyl, propenyl, propargyl, propynyl, -CHF 2 , -CF 3 , -CHFCH 2 F, - CF 2 CHF 2 , -CH 2 CF 3 , -CH 2 CF 2 CHF 2 , methoxy, ethoxy, n-propoxy, isopropoxy, -OCHF 2 , -OCF 3 , -OCHFCH 2 F, -OCF 2 CHF 2 , -OCH 2 CF 3 , -OCH 2 CF 2 CHF 2 , methylamino, dimethylamino, ethylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropenyl, cyclo Butenyl, cyclopentenyl, cyclo
- R 3 is C 6-10 aryl or 5-10 membered heteroaryl, wherein said C 6-10 aryl and 5-10 membered heteroaryl are independently optionally separated by n R y replaced.
- R is Among them, the said independently optionally substituted with n R ys .
- R 2a , R 2b , R 2c , R 2d , and R 2e are each independently hydrogen, deuterium, fluorine, chlorine, bromine, iodine, hydroxy, amino, nitro, cyano, C 1-4 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy or C 1-4 alkylamino; wherein, the C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy and C 1-4 Alkylamino is independently optionally 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxy, oxo, amino, nitro, cyano, C 1-3 alkyl, C 1-3 substituted by groups of haloalkyl, C 1-3 alkoxy,
- R 2a , R 2b , R 2c , R 2d , and R 2e are each independently hydrogen, deuterium, fluorine, chlorine, bromine, iodine, hydroxy, amino, nitro, cyano, methyl, ethyl radical, n-propyl, isopropyl, allyl, propenyl, propargyl, propynyl, -CHF 2 , -CF 3 , -CHFCH 2 F, -CF 2 CHF 2 , -CH 2 CF 3 , -CH 2 CF 2 CHF 2 , methoxy, ethoxy, n-propoxy, isopropoxy, -OCHF 2 , -OCF 3 , -OCHFCH 2 F, -OCF 2 CHF 2 , -OCH 2 CF 3 , -OCH 2 CF 2 CHF 2 , methylamino, dimethylamino or ethylamino;
- each R x is independently deuterium, fluorine, chlorine, bromine, iodine, hydroxy, oxo, amino, nitro, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, C 1-4 alkylamino, C 3-6 cycloalkyl or 3-6 membered heterocycle wherein, the C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy , C 1-4 alkylamino, C 3-6 cycloalkyl and 3-6 membered heterocyclyl independently optionally by 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxygen substituted, amino, nitro, cyano, C 1-3 alkyl, C 3-6 cyclo
- each Rx is independently deuterium, fluorine, chlorine, bromine, iodine, hydroxy, oxo, amino, nitro, cyano, methyl, ethyl, n-propyl, isopropyl, alkene Propyl, propenyl, propargyl, propynyl, -CHF 2 , -CF 3 , -CHFCH 2 F, -CF 2 CHF 2 , -CH 2 CF 3 , -CH 2 CF 2 CHF 2 , methoxy , ethoxy, n-propoxy, isopropoxy, -OCHF 2 , -OCF 3 , -OCHFCH 2 F, -OCF 2 CHF 2 , -OCH 2 CF 3 , -OCH 2 CF 2 CHF 2 , methylamino , dimethylamino, ethylamino, cyclopropyl, cyclobutyl, cycl
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the present invention, or a stereoisomer, geometric isomer, tautomer, nitroxide, hydrate, or solvate thereof , metabolites, pharmaceutically acceptable salts or prodrugs thereof, and pharmaceutically acceptable carriers, excipients, diluents, adjuvants, vehicles or combinations thereof.
- the present invention relates to the use of the aforementioned compound or a pharmaceutical composition thereof in the manufacture of a medicament for the prevention, treatment or alleviation of KRAS G12C mediated diseases in a patient.
- the KRAS G12C-mediated disease of the invention is cancer.
- the cancer of the present invention is lung cancer, lymphoma, esophageal cancer, ovarian cancer, pancreatic cancer, rectal cancer, brain glioma, cervical cancer, urothelial cancer, gastric cancer, endometrial cancer , liver, bile duct, breast, colon, appendix, small bowel, leukemia and melanoma.
- the present invention relates to methods for the preparation, isolation and purification of compounds represented by formula (I).
- the articles “a”, “an” and “the” are intended to include “at least one” or “one or more” unless stated otherwise or otherwise clearly contradicted by context.
- these articles refer to one or more than one (ie, at least one) object of the article.
- a component refers to one or more components, ie, there may be more than one component contemplated for use or use in the implementation of the described embodiments.
- patient refers to humans (including adults and children) or other animals. In some embodiments, “patient” refers to a human.
- Stereoisomers refer to compounds that have the same chemical structure, but differ in the arrangement of atoms or groups in space. Stereoisomers include enantiomers, diastereomers, conformational isomers (rotamers), geometric isomers (cis/trans isomers), atropisomers, etc. .
- Chiral is a molecule that has the property of being non-superimposable with its mirror image; while “achiral” refers to a molecule that is superimposable with its mirror image.
- Enantiomer refers to two nonsuperimposable, but mirror-image isomers of a compound.
- Diastereomer refers to a stereoisomer having two or more centers of chirality and whose molecules are not mirror images of each other. Diastereomers have different physical properties such as melting point, boiling point, spectral properties and reactivity. Diastereomeric mixtures can be separated by high resolution analytical procedures such as electrophoresis and chromatography, eg HPLC.
- any asymmetric atom (eg, carbon, etc.) of the compounds disclosed herein may exist in racemic or enantiomerically enriched forms, such as (R)-, (S)- or (R,S)-configurations exist.
- each asymmetric atom has at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 70% enantiomeric excess in the (R)- or (S)-configuration 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess.
- the compounds of the present invention may be present as one of the possible isomers or as mixtures thereof, such as racemates and diastereoisomeric mixtures (depending on the number of asymmetric carbon atoms) ) in the form of.
- Optically active (R)- or (S)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be in the E or Z configuration; if the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have the cis or trans configuration.
- any resulting racemate of the final product or intermediate can be resolved into the optical enantiomers by known methods by methods familiar to those skilled in the art, eg, by performing diastereomeric salts thereof obtained. separation. Racemic products can also be separated by chiral chromatography, eg, high performance liquid chromatography (HPLC) using chiral adsorbents.
- enantiomers can be prepared by asymmetric synthesis, for example, see Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Principles of Asymmetric Synthesis (2 nd Ed. Robert E.
- tautomer or "tautomeric form” refers to structural isomers having different energies that are interconvertible through a low energy barrier.
- a chemical equilibrium of tautomers can be achieved if tautomerism is possible (eg, in solution).
- protontautomers also known as prototropic tautomers
- Valence tautomers include interconversions by recombination of some of the bonding electrons.
- keto-enol tautomerism is the interconversion of pentane-2,4-dione and 4-hydroxypent-3-en-2-one tautomers.
- tautomerism is phenol-ketone tautomerism.
- a specific example of phenol-ketone tautomerism is the interconversion of pyridin-4-ol and pyridin-4(lH)-one tautomers. Unless otherwise indicated, all tautomeric forms of the compounds of the present invention are within the scope of the present invention.
- substituted means that one or more hydrogen atoms in a given structure have been replaced with a specified substituent.
- the compounds of the present invention may be optionally substituted with one or more substituents, such as the compounds of the general formula above, or as in the Examples, subclasses, and subclasses encompassed by the present invention. a class of compounds.
- substituents such as the compounds of the general formula above, or as in the Examples, subclasses, and subclasses encompassed by the present invention. a class of compounds.
- optionally substituted by is used interchangeably with the term “unsubstituted or substituted by”, ie the structure is unsubstituted or substituted by one or more of the present invention group substitution; when the number of the substituents is greater than 1, the substituents may be the same or different from each other. For example, “optionally substituted by 1, 2, 3, 4 or 5 groups selected from " described in the present invention, when the number of the substituents is greater than 1, the substituents may
- C1-6 alkyl specifically refers to the independently disclosed methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl and C6 alkyl groups .
- C n1-n2 means that the number of carbon atoms contained in the group is n1-n2, both n1 and n2 are natural numbers other than 0, and n2 is greater than n1, and the "n1-n2" includes n1 , n2, and any natural number in between.
- C 1-6 alkyl group represents an alkyl group containing 1-6 carbon atoms
- C 1-6 alkoxy group represents an alkoxy group containing 1-6 carbon atoms
- C 3-6 carbocyclic group represents an alkoxy group containing 3- Carbocyclyl of 6 carbon atoms.
- linking substituents are described.
- the Markush variables listed for that group should be understood to be the linking group.
- the Markush group definition for that variable recites “alkyl” or “aryl”, it should be understood that the “alkyl” or “aryl” respectively represents the linking An alkylene group or an arylene group.
- alkyl or “alkyl group” used in the present invention refers to a saturated linear or branched monovalent hydrocarbon group containing 1 to 20 carbon atoms, wherein the alkyl group may optionally be is substituted with one or more substituents described herein. Unless otherwise specified, alkyl groups contain 1-20 carbon atoms.
- the alkyl group contains 1-12 carbon atoms; in other embodiments, the alkyl group contains 1-6 carbon atoms, denoted as C 1-6 alkyl; in yet other implementations In the scheme, the alkyl group contains 1-4 carbon atoms, denoted as C 1-4 alkyl; also in some embodiments, the alkyl group contains 1-3 carbon atoms, denoted as C 1-3 alkane base.
- alkyl groups include, but are not limited to, methyl (Me, -CH3 ), ethyl (Et, -CH2CH3), n - propyl (n - Pr, -CH2CH2CH3 ) ), isopropyl (i-Pr, -CH(CH 3 ) 2 ), n-butyl (n-Bu, -CH 2 CH 2 CH 2 CH 3 ), isobutyl (i-Bu, -CH 2 CH ) (CH 3 ) 2 ), sec-butyl (s-Bu, -CH(CH 3 )CH 2 CH 3 ), tert-butyl (t-Bu, -C(CH 3 ) 3 ), n-pentyl (-CH 2CH2CH2CH2CH3), 2 -pentyl (-CH( CH3 ) CH2CH2CH3 ) , 3 - pentyl (-CH( CH2CH3 ) 2 ) , 2 -methyl
- alkenyl refers to a linear or branched monovalent hydrocarbon group containing 2 to 12 carbon atoms, wherein there is at least one site of unsaturation, i.e., a carbon-carbon sp 2 double bond, wherein the alkenyl group A group can be optionally substituted with one or more substituents described herein, including the “cis” and “trans” positions, or the “E” and “Z” positions.
- an alkenyl group contains 2-8 carbon atoms; in another embodiment, an alkenyl group contains 2-6 carbon atoms, denoted as C 2-6 alkenyl; in yet another embodiment In the scheme, alkenyl groups contain 2-4 carbon atoms and are denoted as C 2-4 alkenyl.
- alkynyl refers to a linear or branched monovalent hydrocarbon group containing 2-12 carbon atoms, wherein there is at least one site of unsaturation, i.e., a carbon-carbon sp triple bond, wherein the alkynyl group Can be optionally substituted with one or more of the substituents described herein.
- the alkynyl group contains 2-8 carbon atoms; in other embodiments, the alkynyl group contains 2-6 carbon atoms, denoted as C 2-6 alkynyl; in still other implementations In the scheme, alkynyl groups contain 2-4 carbon atoms and are denoted as C 2-4 alkenyl.
- alkynyl groups include, but are not limited to, ethynyl (-C ⁇ CH), propargyl (-CH2C ⁇ CH), 1 -propynyl (propynyl, -C ⁇ C-CH) 3 ) and so on.
- alkoxy means that an alkyl group is attached to the remainder of the molecule through an oxygen atom, wherein the alkyl group has the meaning as described herein. Unless otherwise specified, the alkoxy groups contain 1-12 carbon atoms. In some embodiments, alkoxy groups contain 1-6 carbon atoms, denoted C 1-6 alkoxy; in other embodiments, alkoxy groups contain 1-4 carbon atoms, denoted is C 1-4 alkoxy; in yet other embodiments, the alkoxy group contains 1-3 carbon atoms, denoted as C 1-3 alkoxy.
- the alkoxy groups may be optionally substituted with one or more substituents described herein.
- alkoxy groups include, but are not limited to, methoxy (MeO, -OCH 3 ), ethoxy (EtO, -OCH 2 CH 3 ), 1-propoxy (n-PrO, n- Propoxy, -OCH 2 CH 2 CH 3 ), 2-propoxy (i-PrO, i-propoxy, -OCH(CH 3 ) 2 ), 1-butoxy (n-BuO, n- Butoxy, -OCH 2 CH 2 CH 2 CH 3 ), 2-methyl-l-propoxy (i-BuO, i-butoxy, -OCH 2 CH(CH 3 ) 2 ), 2-butanyl Oxy (s-BuO, s-butoxy, -OCH(CH 3 )CH 2 CH 3 ), 2-methyl-2-propoxy (t-BuO, t-butoxy, -OC(CH 3 ) 3 ), 1 -pentyloxy (n - pentyloxy, -OCH2CH2CH2CH2CH2
- haloalkyl or “haloalkoxy” denotes an alkyl or alkoxy group substituted with one or more halogen atoms, wherein the alkyl group and the alkoxy group are as specifically defined herein. Such examples include, but are not limited to, trifluoromethyl, trifluoromethoxy, and the like.
- hydroxyalkoxy refers to an alkoxy group substituted with one or more hydroxy groups, examples of which include, but are not limited to, -OCH2OH , -OCH2CH2OH , and the like.
- Carbocyclyl or “carbocycle” refers to a monovalent or polyvalent non-aromatic saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system containing from 3 to 12 carbon atoms.
- Carbobicyclyl groups include spirocarbobicyclyl, fused carbobicyclyl, and bridged carbobicyclyl groups, and suitable carbocyclyl groups include, but are not limited to, cycloalkyl, cycloalkenyl, and cycloalkynyl.
- carbocyclyl groups further include, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopentyl-1-enyl, 1-cyclopentyl-2-enyl, 1-cyclopentyl- 3-alkenyl, cyclohexyl, 1-cyclohexyl-1-enyl, 1-cyclohexyl-2-enyl, 1-cyclohexyl-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, and the like.
- cycloalkyl refers to a monovalent or polyvalent non-aromatic saturated monocyclic, bicyclic or tricyclic ring system containing 3 to 12 carbon atoms. In some embodiments, the cycloalkyl group contains 3-12 carbon atoms; in other embodiments, the cycloalkyl group contains 3-8 carbon atoms; in still other embodiments, the cycloalkyl group contains 3-6 carbon atoms carbon atom. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. The cycloalkyl group is optionally substituted with one or more substituents described herein.
- heterocycle refers to a monovalent or polyvalent monocyclic, bicyclic, or tricyclic ring system containing 3 to 14 ring atoms, wherein One or more atoms on the ring are independently replaced by a heteroatom having the meaning as defined in the present invention, the ring may be fully saturated or contain one or more degrees of unsaturation, but an aromatic ring may be not allowed.
- a “heterocycle”, “heterocyclyl” or “heterocyclic” group is a 3-8 membered monocyclic ring (2-6 carbon atoms and selected from N, O, P, S 1-3 heteroatoms, where S or P are optionally substituted with one or more oxygen atoms to give groups like SO, SO2, PO, PO2 ) , or a 7-12 membered bicyclic ring ( 4 - 9 carbon atoms and 1-3 heteroatoms selected from N, O, P, S, where S or P is optionally substituted by one or more oxygen atoms to give like SO, SO 2 , PO, PO 2 groups).
- a “heterocycle”, “heterocyclyl” or “heterocyclic” group is a 3-6 membered monocyclic ring (2-4 carbon atoms and selected from N, O, P, 1-3 heteroatoms of S, where S or P are optionally substituted by one or more oxygen atoms to give groups like SO, SO2, PO, PO2 ) .
- the heterocyclyl group is optionally substituted with one or more substituents described herein.
- heterocyclyl groups include, but are not limited to, oxiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl , pyrazolinyl, pyrazolidine, imidazolinyl, imidazolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, 1,3-dioxocyclopentyl, disulfide Amyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl , Dioxanyl, Dithianyl, Thioxanyl, Homopiperazinyl, Homopiperi
- oxidized sulfur atoms in a heterocyclyl group include, but are not limited to, sulfolane, thiomorpholinyl 1,1-dioxide, and the like.
- the heterocyclyl group is optionally substituted with one or more substituents described herein.
- aryl refers to monocyclic, bicyclic and tricyclic carbocyclic ring systems containing 6-14 ring atoms, or 6-12 ring atoms, or 6-10 ring atoms, wherein at least one ring system is aromatic A family of rings in which each ring system contains a ring of 3-7 atoms with one or more points of attachment to the rest of the molecule.
- aryl is used interchangeably with the term “aromatic ring”. Examples of aryl groups may include phenyl, naphthyl, and anthracenyl. The aryl group is optionally substituted with one or more substituents described herein.
- heteroaryl or “heteroaromatic ring” means a monovalent or polyvalent monocyclic, bicyclic or tricyclic ring containing 5-14 ring atoms, or 5-10 ring atoms, or 5-6 ring atoms A system in which at least one ring is aromatic and at least one ring contains one or more heteroatoms.
- a heteroaryl group is usually, but not necessarily, attached to the parent molecule through the aromatic ring of the heteroaryl group.
- heteroaryl may be used interchangeably with the terms “heteroaromatic ring” or “heteroaromatic”.
- the heteroaryl group is optionally substituted with one or more substituents described herein.
- heteroaryl groups of 5-10 ring atoms contain 1, 2, 3, or 4 heteroatoms independently selected from O, S, and N; in other embodiments, 5-6 rings Atomic heteroaryl is a monocyclic ring system and contains 1, 2, 3 or 4 heteroatoms independently selected from O, S and N.
- heteroaryl groups include, but are not limited to, 2-furyl, 3-furyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl , 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2- Pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (such as 3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (such as 5-tetrazolyl), triazolyl (such as 2-triazolyl and 5-triazolyl), 2-thienyl, 3-thienyl, pyrazolyl (such as 2-thi
- nitrogen-containing monocyclic ring refers to a monocyclic ring of 4-8 ring atoms containing 1 or 2 nitrogen atoms, the ring may be fully saturated or contain one or more degrees of saturation, but not aromatic.
- monocyclic rings containing nitrogen atoms include, but are not limited to, azetidine, pyrrolidine, piperidine, piperazine, and the like.
- the nitrogen-containing monocyclic ring is optionally substituted with one or more substituents described herein.
- fused bicyclic means a monovalent or polyvalent saturated or Partially unsaturated ring system
- the ring system refers to a non-aromatic bicyclic ring system, the two rings in the ring system share two adjacent carbon atoms.
- Such systems may contain independent or conjugated unsaturated systems, but whose core structure does not contain aromatic rings or aromatic heterocycles (although aromatic groups may serve as substituents thereon).
- nitrogen-containing fused ring refers to a fused ring containing 1 or 2 nitrogen atoms, and examples of nitrogen-containing fused rings include, but are not limited to, octahydropyrrolo[3,4-c]pyrrole, and the like .
- the fused ring is optionally substituted with one or more substituents described herein.
- spirocyclyl spirocycle
- spirobicyclyl spirobicyclyl
- spirobicyclyl spirobicyclyl
- nitrogen-containing spirocycle refers to a spirocycle containing 1 or 2 nitrogen atoms
- nitrogen-containing spirocycles include, but are not limited to, 2,7-diazaspiro[3.5]nonane , 2,6-diazaspiro[3.3]heptane and so on.
- the spiro ring is optionally substituted with one or more substituents described herein.
- bridged ring or “bridged ring group” refers to a saturated or partially unsaturated bridged ring system, involving a non-aromatic bicyclic ring system, such as shown in formula (b), that is, ring A1 and ring A2 share an alkane chain or A heteroalkane chain wherein each X3 is independently optionally a carbon atom or a heteroatom and j is 1, 2, 3 or 4.
- Such systems contain 5-12 ring atoms, may contain independent or conjugated unsaturation, but their core structure does not contain aromatic or aromatic rings (although aromatics may be used as substituents thereon).
- nitrogen-containing bridged ring refers to a bridged ring containing 1 or 2 nitrogen atoms
- nitrogen-containing bridged rings include, But not limited to, (1R,5S)-3,8-diazabicyclo[3.2.1]octane and the like.
- the bridged ring is optionally substituted with one or more substituents described herein.
- j-k ring atoms or "j-k membered” are used interchangeably herein to mean that the cyclic group consists of j-k ring atoms including carbon atoms and/or O, Hetero atoms such as N, S, P, etc.
- the j and k are each independently any non-zero natural number, and k>j; the "j-k” includes j, k and any natural number in between.
- 3-8 atoms or 3-8 elements means the cyclic group consists of 3-8 (ie, 3, 4, 5, 6, 7 or 8), 3-6 (ie, 3, 4, 5 or 6), 5-10 (ie, 5, 6, 7, 8, 9 or 10) or 5-6 (ie, 5 or 6) ring atoms including carbon atoms and/or O , N, S, P and other heteroatoms.
- heteroaryl of 5-10 ring atoms or “heteroaryl of 5-10 members” means that it includes a heteroaryl group of 5, 6, 7, 8, 9, or 10 ring atoms wherein 5, 6, 7, 8, 9 or 10 represent the number of ring atoms, eg pyridyl is a heteroaryl or 6-membered heteroaryl consisting of 6 ring atoms.
- heteroatom refers to O, S, N, P, and Si, including N, S, and P in any oxidation state; in the form of primary, secondary, tertiary amines, and quaternary ammonium salts; or on a nitrogen atom in a heterocyclic ring.
- Hydrogen substituted form for example, N (like N in 3,4-dihydro-2H-pyrrolidinyl), NH (like NH in pyrrolidinyl) or NR (like in N-substituted pyrrolidinyl) NR, R are the substituents described in the present invention).
- halogen or "halogen atom” refers to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I).
- alkylamino or “alkylamino” includes “N-alkylamino” and "N,N-dialkylamino” wherein the amino group is independently substituted with one or two alkyl groups, respectively.
- the alkylamino group is an alkylamino group formed by one or two C1-6 alkyl groups attached to a nitrogen atom.
- the alkylamino group is an amino group substituted with one or two C1-3 alkyl groups.
- Suitable alkylamino groups may be monoalkylamino or dialkylamino, examples of which include, but are not limited to, N-methylamino (methylamino), N-ethylamino (ethylamino), N,N -Dimethylamino (dimethylamino), N,N-diethylamino (diethylamino), etc.
- aminoalkyl includes a C 1-10 straight or branched chain alkyl group substituted with one or more amino groups.
- the aminoalkyl group is a C 1-6 aminoalkyl group substituted with one or more amino groups, such examples include, but are not limited to, aminomethyl, aminoethyl, aminopropyl , aminobutyl and aminohexyl.
- the ring system formed by the substituent (R x ) m being attached to the central ring by a bond represents m substituents R x can be carried out at any substitutable position or any reasonable position on the present ring. replace.
- Formula d represents that the G ring may be substituted with m Rx, and when m is greater than 1 , each Rx may be independently selected from the same or different substituent groups.
- An attachment point can be attached to the rest of the molecule at any linkable position on the loop as described herein.
- formula e represents that any position on the C-ring or the D-ring that may be attached can serve as a point of attachment.
- linking sites on the substructure of the group X there are two linking sites on the substructure of the group X that can be connected to the rest of the molecule, and the linking modes of the two linking sites can be interchanged.
- X is When the general formula (I) of the present invention represents that the N connecting end on X 1 is connected to R 1 , and the other C connecting end is connected to the rest of the general formula (I), as shown in formula f; or that the C connecting end on X is connected R 1 , the other N-connected end connecting the rest of formula (I),
- protecting group refers to a substituent group that is commonly used to block or protect specific functionality when it reacts with other functional groups.
- amino protecting group refers to a substituent attached to the amino group to block or protect the functionality of the amino group in the compound. Suitable amino protecting groups include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC, Boc), benzyloxycarbonyl (CBZ, Cbz) and 9-fluorenemethyleneoxycarbonyl (Fmoc).
- hydroxyl protecting group refers to a substituent of a hydroxy group used to block or protect the functionality of the hydroxy group
- suitable protecting groups include acetyl and silyl.
- Carboxyl protecting group means that the substituent of the carboxyl group is used to block or protect the functionality of the carboxyl group.
- General carboxyl protecting groups include -CH 2 CH 2 SO 2 Ph, cyanoethyl, 2-(trimethylsilane) yl)ethyl, 2-(trimethylsilyl)ethoxymethyl, 2-(p-toluenesulfonyl)ethyl, 2-(p-nitrobenzenesulfonyl)ethyl, 2-(diphenyl) phosphino)ethyl, nitroethyl, and the like.
- protecting groups reference can be made to the literature: TW. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991; and PJ Kocienski, Protecting Groups, Thieme, Stuttgart, 2005.
- pharmaceutically acceptable refers to molecular entities and compositions that are physiologically tolerable when administered to humans and generally do not produce allergic or similar inappropriate reactions, such as gastrointestinal upset, dizziness, and the like.
- pharmaceutically acceptable as used herein means approved by a federal regulatory agency or a national government or listed in the US Pharmacopeia or other generally recognized pharmacopeia for use in animals, particularly in humans.
- carrier refers to a diluent, adjuvant, excipient or base with which the compound is administered.
- These pharmaceutical carriers can be sterile liquids such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
- Water and Aqueous Solutions Saline solutions and aqueous dextrose and glycerol solutions are preferred for use as carriers, especially for injectable solutions. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences” by E.W. Martin.
- prodrug refers to the conversion of a compound into a compound of formula (I) in vivo. Such conversion is effected by hydrolysis of the prodrug in blood or enzymatic conversion to the parent structure in blood or tissue.
- the prodrug compounds of the present invention can be esters.
- esters that can be used as prodrugs include phenyl esters, aliphatic (C 1-24 ) esters, acyloxymethyl esters, carbonate esters , carbamates and amino acid esters.
- a compound that contains a hydroxyl group can be acylated to give the compound in prodrug form.
- prodrug forms include phosphates, such as these phosphates are phosphorylated by the hydroxyl group on the parent.
- phosphates such as these phosphates are phosphorylated by the hydroxyl group on the parent.
- a complete discussion of prodrugs can be found in the following literature: T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the ACSSymposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, J. Rautio et al., Prodrugs: Design and Clinical Applications, Nature Review Drug Discovery, 2008, 7, 255-270, and SJ Hecker et al., Prodrugs of Phosphates and Phosphonates, Journal of Medicinal Chemistry , 2008, 51, 2328-2345.
- Metal refers to a product obtained by metabolism of a specific compound or salt thereof in vivo. Metabolites of a compound can be identified by techniques well known in the art, and their activity can be characterized using assays as described herein. Such products may be obtained by subjecting the administered compound to oxidation, reduction, hydrolysis, amidation, deamidation, esterification, delipidation, enzymatic cleavage, and the like. Accordingly, the present invention includes metabolites of compounds, including metabolites produced by contacting a compound of the present invention with a mammal for a sufficient period of time.
- pharmaceutically acceptable salts refer to organic and inorganic salts of the compounds of the present invention.
- Pharmaceutically acceptable salts are well known in the art, as described in the literature: S.M.Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66:1-19.
- Pharmaceutically acceptable non-toxic acid salts include, but are not limited to, inorganic acid salts such as hydrochloride, hydrobromide, phosphate, sulfate, perchlorate, and organic acid salts such as Acetate, oxalate, maleate, tartrate, citrate, succinate, malonate, etc., or obtain these salts by other methods described in books such as ion exchange.
- Pharmaceutically acceptable base addition salts include, but are not limited to, inorganic base salts, such as ammonium salts and metal salts of Groups I to XII of the periodic table, and organic base salts, such as those formed with primary, secondary, and tertiary amines. Salt.
- a “solvate” of the present invention refers to an association of one or more solvent molecules with a compound of the present invention.
- Solvate-forming solvents include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid, and aminoethanol.
- hydrate refers to an association in which the solvent molecule is water.
- any disease or disorder in some embodiments refers to ameliorating the disease or disorder (ie, slowing or arresting or alleviating the development of the disease or at least one clinical symptom thereof). In other embodiments, “treating” refers to alleviating or improving at least one physical parameter, including a physical parameter that may not be perceived by a patient. In other embodiments, “treating” refers to modulating a disease or disorder physically (eg, stabilizing an observable symptom) or physiologically (eg, stabilizing a physical parameter), or both. In other embodiments, “treating” refers to preventing or delaying the onset, occurrence or worsening of a disease or disorder.
- terapéuticaally effective amount refers to an amount of a compound that, when administered to a subject to treat a disease, is sufficient to effect the treatment of such disease.
- a “therapeutically effective amount” can vary depending on the compound, the disease and severity, and the condition, age, weight, sex, etc. of the subject to be treated.
- the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound, basic or acidic moieties, using conventional chemical methods.
- such salts can be prepared by reacting the free acid forms of these compounds with a stoichiometric amount of a suitable base (eg, hydroxide, carbonate, bicarbonate, etc. of Na, Ca, Mg, or K), or by The preparations are carried out by reacting the free base forms of these compounds with a stoichiometric amount of the appropriate acid.
- a suitable base eg, hydroxide, carbonate, bicarbonate, etc. of Na, Ca, Mg, or K
- Such reactions are usually carried out in water or an organic solvent or a mixture of the two.
- non-aqueous media such as diethyl ether, ethyl acetate, ethanol, isopropanol or acetonitrile is required.
- non-aqueous media such as diethyl ether, ethyl acetate, ethanol, isopropanol or acetonitrile.
- the compounds disclosed herein, including their salts can also be obtained in their hydrate form or in a form containing a solvent (eg, ethanol, DMSO, etc.) for their crystallization.
- a solvent eg, ethanol, DMSO, etc.
- Compounds of the present disclosure may form solvates, inherently or by design, with pharmaceutically acceptable solvents, including water; thus, the present invention is intended to include both solvated and unsolvated forms.
- Isotopically enriched compounds have the structures depicted by the general formulae given herein, except that one or more atoms are replaced by atoms having a selected atomic weight or mass number.
- Exemplary isotopes that can be incorporated into the compounds of the present invention include isotopes of hydrogen , carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as 2H, 3H , 11C , 13C , 14C , 15N , 17O , 18 O, 18 F, 31 P, 32 P, 35 S, 36 Cl and 125 I.
- Isotopically enriched compounds of the present invention can be prepared by conventional techniques familiar to those skilled in the art or as described in the Examples and Preparations of this invention, using a suitable isotopically labeled reagent in place of the previously used unlabeled reagent.
- cancer refers to or describes a physiological condition in a patient that is often characterized by uncontrolled cell growth.
- a “tumor” includes one or more cancer cells. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia, or lymphoid malignancies.
- cancers include squamous cell carcinoma (eg, epithelial squamous cell carcinoma), lung cancer (including small cell lung cancer, non-small cell lung cancer (NSCLC), lung adenocarcinoma, and lung squamous cell carcinoma), esophageal cancer, Peritoneal cancer, hepatocellular cancer, gastric or stomach cancer (including gastrointestinal cancer), pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatocellular carcinoma hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, appendix cancer, small bowel cancer, endometrial or uterine cancer, salivary gland cancer, kidney or renal cancer, prostate cancer, Cancer of the vulva, thyroid, liver, anus, penis, and head and neck.
- squamous cell carcinoma eg, epithelial squamous cell carcinoma
- lung cancer including small cell lung cancer, non-small cell lung cancer (NSCLC), lung
- KRAS G12C inhibitor used in the present invention refers to a substance that can bind to KRAS G12C and inhibit its activity.
- the present invention provides a compound or a pharmaceutical composition thereof, which can act as an inhibitor of KRAS, especially KRAS G12C.
- the present invention further relates to the use of the compound or a pharmaceutical composition thereof for the manufacture of a medicament for the treatment of a disease and/or disorder by inhibiting the activity of KRAS G12C with the compound.
- the present invention further describes methods of synthesizing the compounds.
- the compounds of the present invention exhibit improved biological activity and pharmacokinetic properties.
- the present invention relates to a compound, which is a compound represented by formula (I), or a stereoisomer, geometric isomer, tautomer, nitroxide of a compound represented by formula (I) compounds, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs,
- each of X, Y, Z, R 1 , R 2a , R 2b , R 2c , R 2d and R 3 has the meaning described in the present invention.
- X is -LX 1 -, wherein L is a bond or NH, and X 1 is a nitrogen-containing 4-8 membered monocyclic, 5-12 membered fused ring, 5-12 membered spirocyclic ring, or 5-membered -12-membered bridged rings, the 4-8-membered monocycles, 5-12-membered fused rings, 5-12-membered spiro rings, and 5-12-membered bridged rings can be independently optionally substituted with m Rx ; wherein Rx and m have the meaning described in the present invention.
- the 4-8-membered monocyclic ring, 5-12-membered fused ring, 5-12-membered spirocyclic ring or 5-12-membered bridged ring containing nitrogen atoms in the present invention refers to the single ring, fused ring, spiro ring Rings and bridged rings each independently contain 1 or 2 nitrogen atoms.
- X is wherein Rx and m have the meanings described in the present invention.
- Y is N or CH.
- Z is N or CR 2e ; wherein R 2e has the meaning described herein.
- R a is hydrogen, deuterium, halogen atom, C 1-3 alkyl, C 1-3 haloalkyl or C 1-3 alkoxy, wherein the C 1-3 alkyl, C 1-3 haloalkyl and C 1-3 alkoxy independently optionally by 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxo, amino, nitro, cyano , C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 haloalkoxy and C 1-3 hydroxyalkoxy.
- Ra is hydrogen, deuterium, halogen, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, methoxy, ethoxy, or isopropyl Propoxy, wherein said methyl, ethyl, n-propyl, isopropyl, difluoromethyl, methoxy, ethoxy and isopropoxy are independently optionally substituted by 1, 2, 3 , 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxo, amino, nitro, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl , methoxy, ethoxy, isopropoxy, trifluoromethoxy, -OCH 2 OH and -OCH 2 CH 2 OH groups.
- R b is hydrogen, deuterium, halogen atom, C 1-3 alkyl, C 1-3 haloalkyl or C 1-3 alkoxy, wherein the C 1-3 alkyl, C 1-3 haloalkyl and C 1-3 alkoxy independently optionally by 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxo, amino, nitro, cyano , C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 haloalkoxy and C 1-3 hydroxyalkoxy.
- R is hydrogen, deuterium , halogen, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, methoxy, ethoxy, or isopropyl Propoxy, wherein said methyl, ethyl, n-propyl, isopropyl, difluoromethyl, methoxy, ethoxy and isopropoxy are independently optionally substituted by 1, 2, 3 , 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxo, amino, nitro, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl , methoxy, ethoxy, isopropoxy, trifluoromethoxy, -OCH 2 OH and -OCH 2 CH 2 OH groups.
- R c is hydrogen, deuterium, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkylamino, 5-6 membered heteroaryl, C 3-6 carbocyclic or 3-6 membered heterocyclic, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkylamino, 5-6 membered heteroaryl group, C 3-6 carbocyclyl and 3-6 membered heterocyclyl independently optionally by 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxo, amino, nitro , cyano, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy
- Rc is hydrogen, deuterium, methyl, ethyl, n-propyl, isopropyl, allyl, propenyl, propargyl, propynyl, -CHF2 , -CF3 , -CHFCH 2 F, -CF 2 CHF 2 , -CH 2 CF 3 , -CH 2 CF 2 CHF 2 , methoxy, ethoxy, n-propoxy, isopropoxy, -OCHF 2 , -OCF 3 , -OCHFCH 2 F, -OCF 2 CHF 2 , -OCH 2 CF 3 , -OCH 2 CF 2 CHF 2 , methylamino, dimethylamino, ethylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclo Hexyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, methylamino
- R 3 is C 6-12 aryl or 5-10 membered heteroaryl, wherein said C 6-12 aryl and 5-10 membered heteroaryl are independently optionally separated by n R y is substituted; wherein n is 1, 2, 3, 4, 5, 6 or 7, and R y has the meaning described herein.
- R 3 is C 6-10 aryl or 5-10 membered heteroaryl, wherein said C 6-10 aryl and 5-10 membered heteroaryl are independently optionally surrounded by n Ry is substituted; n is 1, 2, 3, 4, 5, 6 or 7, wherein Ry has the meaning described herein.
- R3 is Among them, the said independently optionally substituted with n R y ; wherein n is 1, 2, 3, 4, 5, 6 or 7 and R y has the meaning described herein.
- R 2a is hydrogen, deuterium, fluorine, chlorine, bromine, iodine, hydroxy, amino, nitro, cyano, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkyne group, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy or C 1-6 alkylamino; wherein, the C 1-6 alkyl, C 2-6 alkenyl , C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy and C 1-6 alkylamino are independently optionally replaced by 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxo, amino, nitro, cyano, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 substituted with haloalkoxy and C 1-3 hydroxyalkoxy groups.
- R 2a is hydrogen, deuterium, fluorine, chlorine, bromine, iodine, hydroxy, amino, nitro, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 Alkynyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy or C 1-4 alkylamino; wherein, the C 1-4 alkyl, C 2-4 alkene group, C 2-4 alkynyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy and C 1-4 alkylamino are independently optionally replaced by 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxo, amino, nitro, cyano, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1- 3 haloalkoxy and C 1-3 hydroxyalkoxy groups are substituted.
- R 2a is hydrogen, deuterium, fluorine, chlorine, bromine, iodine, hydroxy, amino, nitro, cyano, methyl, ethyl, n-propyl, isopropyl, allyl, propenyl, propargyl, propynyl, -CHF 2 , -CF 3 , -CHFCH 2 F, -CF 2 CHF 2 , -CH 2 CF 3 , -CH 2 CF 2 CHF 2 , methoxy, ethoxy radical, n-propoxy, isopropoxy, -OCHF 2 , -OCF 3 , -OCHFCH 2 F, -OCF 2 CHF 2 , -OCH 2 CF 3 , -OCH 2 CF 2 CHF 2 , methylamino, dimethyl Amino or ethylamino; wherein, the methyl, ethyl, n-propyl, isopropy
- R 2b is hydrogen, deuterium, fluorine, chlorine, bromine, iodine, hydroxy, amino, nitro, cyano, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkyne group, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy or C 1-6 alkylamino; wherein, the C 1-6 alkyl, C 2-6 alkenyl , C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy and C 1-6 alkylamino are independently optionally replaced by 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxo, amino, nitro, cyano, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 substituted with haloalkoxy and C 1-3 hydroxyalkoxy groups.
- R 2b is hydrogen, deuterium, fluorine, chlorine, bromine, iodine, hydroxy, amino, nitro, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 Alkynyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy or C 1-4 alkylamino; wherein, the C 1-4 alkyl, C 2-4 alkene group, C 2-4 alkynyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy and C 1-4 alkylamino are independently optionally replaced by 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxo, amino, nitro, cyano, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1- 3 haloalkoxy and C 1-3 hydroxyalkoxy groups are substituted.
- R 2b is hydrogen, deuterium, fluorine, chlorine, bromine, iodine, hydroxy, amino, nitro, cyano, methyl, ethyl, n-propyl, isopropyl, allyl, propenyl, propargyl, propynyl, -CHF 2 , -CF 3 , -CHFCH 2 F, -CF 2 CHF 2 , -CH 2 CF 3 , -CH 2 CF 2 CHF 2 , methoxy, ethoxy radical, n-propoxy, isopropoxy, -OCHF 2 , -OCF 3 , -OCHFCH 2 F, -OCF 2 CHF 2 , -OCH 2 CF 3 , -OCH 2 CF 2 CHF 2 , methylamino, dimethyl Amino or ethylamino; wherein, the methyl, ethyl, n-propyl, isopropy
- R 2c is hydrogen, deuterium, fluorine, chlorine, bromine, iodine, hydroxy, amino, nitro, cyano, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkyne group, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy or C 1-6 alkylamino; wherein, the C 1-6 alkyl, C 2-6 alkenyl , C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy and C 1-6 alkylamino are independently optionally replaced by 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxo, amino, nitro, cyano, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 substituted with haloalkoxy and C 1-3 hydroxyalkoxy groups.
- R 2c is hydrogen, deuterium, fluorine, chlorine, bromine, iodine, hydroxy, amino, nitro, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 Alkynyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy or C 1-4 alkylamino; wherein, the C 1-4 alkyl, C 2-4 alkene group, C 2-4 alkynyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy and C 1-4 alkylamino are independently optionally replaced by 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxo, amino, nitro, cyano, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1- 3 haloalkoxy and C 1-3 hydroxyalkoxy groups are substituted.
- R 2c is hydrogen, deuterium, fluorine, chlorine, bromine, iodine, hydroxy, amino, nitro, cyano, methyl, ethyl, n-propyl, isopropyl, allyl, propenyl, propargyl, propynyl, -CHF 2 , -CF 3 , -CHFCH 2 F, -CF 2 CHF 2 , -CH 2 CF 3 , -CH 2 CF 2 CHF 2 , methoxy, ethoxy radical, n-propoxy, isopropoxy, -OCHF 2 , -OCF 3 , -OCHFCH 2 F, -OCF 2 CHF 2 , -OCH 2 CF 3 , -OCH 2 CF 2 CHF 2 , methylamino, dimethyl Amino or ethylamino; wherein, the methyl, ethyl, n-propyl, isopropy
- R 2d is hydrogen, deuterium, fluorine, chlorine, bromine, iodine, hydroxy, amino, nitro, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkyne group, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy or C 1-6 alkylamino; wherein, the C 1-6 alkyl, C 2-6 alkenyl , C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy and C 1-6 alkylamino are independently optionally replaced by 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxo, amino, nitro, cyano, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 substituted with haloalkoxy and C 1-3 hydroxyalkoxy groups.
- R 2d is hydrogen, deuterium, fluorine, chlorine, bromine, iodine, hydroxy, amino, nitro, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 Alkynyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy or C 1-4 alkylamino; wherein, the C 1-4 alkyl, C 2-4 alkene group, C 2-4 alkynyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy and C 1-4 alkylamino are independently optionally replaced by 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxo, amino, nitro, cyano, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1- 3 haloalkoxy and C 1-3 hydroxyalkoxy groups are substituted.
- R 2d is hydrogen, deuterium, fluorine, chlorine, bromine, iodine, hydroxy, amino, nitro, cyano, methyl, ethyl, n-propyl, isopropyl, allyl, propenyl, propargyl, propynyl, -CHF 2 , -CF 3 , -CHFCH 2 F, -CF 2 CHF 2 , -CH 2 CF 3 , -CH 2 CF 2 CHF 2 , methoxy, ethoxy radical, n-propoxy, isopropoxy, -OCHF 2 , -OCF 3 , -OCHFCH 2 F, -OCF 2 CHF 2 , -OCH 2 CF 3 , -OCH 2 CF 2 CHF 2 , methylamino, dimethyl Amino or ethylamino; wherein, the methyl, ethyl, n-propyl, isopropy
- R 2e is hydrogen, deuterium, fluorine, chlorine, bromine, iodine, hydroxy, amino, nitro, cyano, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkyne group, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy or C 1-6 alkylamino; wherein, the C 1-6 alkyl, C 2-6 alkenyl , C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy and C 1-6 alkylamino are independently optionally replaced by 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxo, amino, nitro, cyano, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 substituted with haloalkoxy and C 1-3 hydroxyalkoxy groups.
- R 2e is hydrogen, deuterium, fluorine, chlorine, bromine, iodine, hydroxy, amino, nitro, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 Alkynyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy or C 1-4 alkylamino; wherein, the C 1-4 alkyl, C 2-4 alkene group, C 2-4 alkynyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy and C 1-4 alkylamino are independently optionally replaced by 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxo, amino, nitro, cyano, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1- 3 haloalkoxy and C 1-3 hydroxyalkoxy groups are substituted.
- R 2e is hydrogen, deuterium, fluorine, chlorine, bromine, iodine, hydroxy, amino, nitro, cyano, methyl, ethyl, n-propyl, isopropyl, allyl, propenyl, propargyl, propynyl, -CHF 2 , -CF 3 , -CHFCH 2 F, -CF 2 CHF 2 , -CH 2 CF 3 , -CH 2 CF 2 CHF 2 , methoxy, ethoxy radical, n-propoxy, isopropoxy, -OCHF 2 , -OCF 3 , -OCHFCH 2 F, -OCF 2 CHF 2 , -OCH 2 CF 3 , -OCH 2 CF 2 CHF 2 , methylamino, dimethyl Amino or ethylamino; wherein, the methyl, ethyl, n-propyl, isopropy
- each Rx is independently deuterium, fluorine, chlorine, bromine, iodine, hydroxy, oxo, amino, nitro, cyano, C1-6 alkyl, C2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkylamino, C 3-8 cycloalkyl or 3-8 membered heterocycle wherein, the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy , C 1-6 alkylamino, C 3-8 cycloalkyl and 3-8 membered heterocyclyl independently optionally by 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, oxygen substituted, amino, nitro, cyano, C 1-3 alkyl, C 1-3
- each Rx is independently deuterium, fluorine, chlorine, bromine, iodine, hydroxy, oxo, amino, nitro, cyano, C1-4 alkyl, C2-4 alkenyl, C 2-4 alkynyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, C 1-4 alkylamino, C 3-6 cycloalkyl or 3-6 membered hetero Cyclic group; wherein, the C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy group, C 1-4 alkylamino, C 3-6 cycloalkyl and 3-6 membered heterocyclyl independently optionally by 1, 2, 3, 4 or 5 independently selected from deuterium, halogen, hydroxyl, of oxo, amino, nitro, cyano, C 1-3 alkyl
- each Rx is independently deuterium, fluorine, chlorine, bromine, iodine, hydroxy, oxo, amino, nitro, cyano, methyl, ethyl, n-propyl, isopropyl, Allyl, propenyl, propargyl, propynyl, -CHF 2 , -CF 3 , -CHFCH 2 F, -CF 2 CHF 2 , -CH 2 CF 3 , -CH 2 CF 2 CHF 2 , methoxy group, ethoxy, n-propoxy, isopropoxy, -OCHF 2 , -OCF 3 , -OCHFCH 2 F, -OCF 2 CHF 2 , -OCH 2 CF 3 , -OCH 2 CF 2 CHF 2 , methyl Amino, dimethylamino, ethylamino, cyclopropyl, cyclobutyl, cyclopentyl
- the present invention relates to one of the following compounds or stereoisomers, geometric isomers, tautomers, nitrogen oxides, solvates, hydrates, metabolites, Esters, pharmaceutically acceptable salts or prodrugs thereof, but in no way limited to:
- the present invention relates to pharmaceutical compositions comprising stereoisomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites of the aforementioned compounds Products, pharmaceutically acceptable salts or prodrugs, and pharmaceutically acceptable carriers, excipients, diluents, adjuvants, vehicles, or any combination thereof.
- the present invention relates to the use of the aforementioned compound or a pharmaceutical composition thereof in the manufacture of a medicament for preventing, treating or alleviating a KRAS G12C mediated disease in a patient.
- the KRAS G12C mediated disease is cancer.
- the cancer of the present invention is lung cancer, lymphoma, esophageal cancer, ovarian cancer, pancreatic cancer, rectal cancer, brain glioma, cervical cancer, urothelial cancer, gastric cancer, endometrial cancer , liver, bile duct, breast, colon, appendix, small bowel, leukemia and melanoma.
- the present invention relates to methods for the preparation, isolation and purification of compounds represented by formula (I).
- the pharmaceutical composition of the present invention features a compound represented by formula (I), a compound listed in the present invention, or a compound of the examples, and a pharmaceutically acceptable carrier.
- the amount of the compound in the pharmaceutical composition of the present invention is effective to treat or alleviate a KRAS G12C mediated disease in a patient.
- pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable prodrugs, salts, esters, salts of esters, or any other that can be administered directly or indirectly according to the needs of the patient Adducts or derivatives, compounds described in other aspects of the invention, metabolites thereof or residues thereof.
- compositions of the present invention further comprise a pharmaceutically acceptable carrier, adjuvant, or excipient, as used herein, including any solvent, diluent, or other Liquid excipients, dispersing or suspending agents, surfactants, isotonic agents, thickening agents, emulsifiers, preservatives, solid binders or lubricants, etc., are suitable for the particular target dosage form.
- a pharmaceutically acceptable carrier including any solvent, diluent, or other Liquid excipients, dispersing or suspending agents, surfactants, isotonic agents, thickening agents, emulsifiers, preservatives, solid binders or lubricants, etc.
- Substances that can be used as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, aluminum, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, sorbitan Potassium acid, partial glyceride mixture of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silicon, magnesium trisilicate, polyethylene Pyrrolidones, polyacrylates, waxes, polyethylene-polyoxypropylene-blocking polymers, lanolin, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as carboxymethyl Sodium cellulose, ethyl cellulose and cellulose acetate; gum powder; malt; gelatin; talc; adjuvants such as
- the compound is administered in admixture with a suitable pharmaceutical diluent, excipient, or carrier (referred to herein as a pharmaceutical carrier) selected according to the form of administration and conventional pharmaceutical practice, which may be an oral tablet, Capsules, elixirs, syrups, and more.
- a suitable pharmaceutical diluent, excipient, or carrier referred to herein as a pharmaceutical carrier
- a pharmaceutical carrier selected according to the form of administration and conventional pharmaceutical practice, which may be an oral tablet, Capsules, elixirs, syrups, and more.
- the active pharmaceutical ingredient may be combined with an oral, non-toxic, pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, glucose, methylcellulose , magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol, etc.; for oral administration in liquid form, the oral pharmaceutical component can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier Combined, such as ethanol, glycerol, water, etc.
- suitable binders, lubricants, disintegrating agents, and coloring agents can also be added to the mixture.
- Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene Ethylene Glycol, Wax, etc.
- Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like.
- Disintegrating agents include, but are not limited to, starch, methylcellulose, agar, bentonite, xanthan gum, and the like.
- the compounds of this invention may be administered in the form of oral dosage forms such as tablets, capsules (each of which includes sustained or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups , and emulsifiers. They may also be administered intravenously (bolus or infusion), intraperitoneally, subcutaneously or intramuscularly, all using dosage forms well known to those of ordinary skill in the art of pharmacy. They may be administered alone, but will generally be administered together with a pharmaceutical carrier selected based on the chosen mode of administration and standard pharmaceutical practice.
- oral dosage forms such as tablets, capsules (each of which includes sustained or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups , and emulsifiers. They may also be administered intravenously (bolus or infusion), intraperitoneally, subcutaneously or intramuscularly, all using dosage forms well known to those of ordinary skill in the art
- the compounds of the present invention can be administered in intranasal form via topical use of a suitable intranasal vehicle, or transdermally via the use of transdermal patches.
- a suitable intranasal vehicle or transdermally via the use of transdermal patches.
- the dose administered is continuous rather than intermittent throughout the period of administration.
- the compounds of the present invention can also be administered in the form of liposomal delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
- Liposomes can be formed from different phospholipids, such as cholesterol, stearylamine, or phosphatidylcholine.
- the compounds of the present invention are also conjugated to soluble polymers that serve as targeted drug carriers.
- soluble polymers include polyvinylpyrrolidone, pyran copolymers, polyhydroxypropyl methacrylate amine-phenol, polyhydroxyethyl aspartamide phenol, or polyethylene oxide-polylysine substituted with palmitoyl residues amino acid.
- the compounds of the present invention can be coupled with a class of biodegradable polymers for achieving controlled drug release, for example, polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, poly ⁇ caprolactone Crosslinked or amphiphilic blocking copolymers of esters, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and hydrogels.
- biodegradable polymers for achieving controlled drug release, for example, polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, poly ⁇ caprolactone Crosslinked or amphiphilic blocking copolymers of esters, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and hydrogels.
- Dosage regimens for compounds of the present invention will vary with known factors such as the pharmacokinetic profile of the particular agent and its mode of administration and route of administration; the race, age, sex, health, medical condition and weight of the recipient; Nature and extent of symptoms; type of concurrent therapy; frequency of therapy; route of administration, patient's renal and hepatic function, and desired effect.
- a physician or veterinarian can make a decision and prescribe an effective amount of the drug to prevent, offset, or stop the development of cancer.
- the daily oral dose of each active ingredient employed is in the range of between about 0.001 to 1000 mg/kg of body weight.
- the most preferred dosage range is from about 1 to about 10 mg/kg body weight/minute during conventional rate infusion.
- the compounds of the present invention may be administered once a day, or may be administered in two, three or four times a day.
- Each unit dose of a dosage form (pharmaceutical composition) suitable for administration may contain from about 1 mg to about 1000 mg of active ingredient.
- the weight of the active ingredient will generally be about 0.5-95% by weight of the total weight of the pharmaceutical composition.
- a compound of the present invention When a compound of the present invention is administered with other therapeutic agents, generally, the amounts of each component in a typical daily dose and in a typical dosage form, relative to the additive or synergistic effects of the therapeutic agents when administered in combination, are The usual dose when administered alone may be reduced.
- the compounds involved in the present invention or their pharmaceutically acceptable salts or their hydrates can be effectively used for preventing, treating or alleviating diseases mediated by KRAS G12C in patients, in particular, they can effectively treat lung cancer, lymphoma, esophageal cancer, ovarian cancer and pancreatic cancer. , rectal cancer, brain glioma, cervical cancer, urothelial cancer, gastric cancer, endometrial cancer, liver cancer, bile duct cancer, breast cancer, colon cancer, appendix cancer, small bowel cancer, leukemia and melanoma, etc.
- the compounds of the present invention can be prepared by the methods described herein, unless otherwise specified, wherein the substituents are as defined herein.
- the following reaction schemes and examples serve to further illustrate the content of the present invention.
- Anhydrous tetrahydrofuran, dioxane, toluene and diethyl ether were obtained by refluxing and drying with metallic sodium.
- Anhydrous dichloromethane and chloroform were obtained by refluxing with calcium hydride.
- Ethyl acetate, petroleum ether, n-hexane, N,N-dimethylacetamide and N,N-dimethylformamide were dried over anhydrous sodium sulfate before use.
- reaction flasks are plugged with suitable rubber stoppers, and the substrate is injected through a syringe. Glassware is dried.
- the chromatographic column is a silica gel column.
- Silica gel 300-400 mesh was purchased from Qingdao Ocean Chemical Factory.
- the measurement conditions for low-resolution mass spectrometry (MS) data are: Agilent 6120 quadrupole HPLC-MS (column model: Zorbax SB-C18, 2.1 ⁇ 30 mm, 3.5 ⁇ m, 6 min, flow rate 0.6 mL/min.
- Mobile phase 5 %-95% ( CH3CN with 0.1% formic acid) in ( H2O with 0.1% formic acid) using electrospray ionization (ESI) at 210 nm/254 nm with UV detection.
- ESI electrospray ionization
- the compound represented by formula ( 15 ) can be prepared by reaction scheme 1: the compound represented by formula ( 1 ) reacts with oxalyl chloride and ammonia water to obtain the compound represented by formula ( 2 ).
- the compound represented by the formula ( 2 ), the compound represented by the formula ( 3 ) and the compound represented by the formula ( 4 ) are reacted to obtain the compound represented by the formula ( 5 ).
- the compound represented by the formula ( 5 ) is reacted under the action of potassium bis(trimethylsilyl)amide to obtain the compound represented by the formula ( 6 ).
- the compound represented by the formula ( 6 ) is reacted under the action of phosphorus oxychloride to obtain the compound represented by the formula ( 7 ).
- the compound represented by the formula ( 7 ) and the compound represented by the formula ( 8 ) are reacted under the action of N,N-diisopropylethylamine to obtain the compound represented by the formula ( 9 ).
- the compound represented by formula ( 11 ) is obtained by reacting with potassium acetate (or cesium carbonate) under the action.
- the compound represented by formula ( 11 ) is in zinc cyanide, bis(tri-tert-butylphosphine) palladium and tri-tert-butylphosphine (or zinc cyanide and chloro(2-dicyclohexylphosphino-2',4', Under the action of 6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II)), the reaction obtained by formula ( 12 ) compounds shown.
- the compound represented by the formula ( 12 ) is de-Boc removed under the action of trifluoroacetic acid to obtain the compound represented by the formula ( 13 ).
- the compound represented by the formula ( 13 ) and the compound represented by the formula ( 14 ) can obtain the compound represented by the formula ( 15 ) under the action of N,N-diisopropylethylamine.
- 2,5,6-Trichloropyridine-3-carboxylic acid (5.0g, 22mmol), dichloromethane (60.0mL) and N,N-dimethylformamide (0.05mL, 0.6mmol) were added to the reaction flask, Cool to 0°C, add oxalyl chloride (2.4mL, 28mmol) dropwise, stir at 0°C for 24h, add ammonia solution in isopropanol (17.0mL, 2.0mol/L, 34mmol), continue stirring for 4h, suction filter, filter cake Washed with dichloromethane (50 mL ⁇ 2), and dried to obtain the title compound as a white solid (1.6 g, yield 32.0%).
- the second step Synthesis of 2,5,6-trichloro-N-((2-isopropyl-4-methylpyridin-3-yl)carbamoyl)nicotinamide
- 2,5,6-Trichloronicotinamide (1.46g, 6.48mmol) and tetrahydrofuran (10mL) were added to the reaction flask, the temperature was raised to 75°C, oxalyl chloride (1.0g, 7.9mmol) was added dropwise, and the reaction was stirred at 75°C for 1 h, Cooled to room temperature, concentrated to remove the solvent, cooled to 0 °C, added tetrahydrofuran (5 mL) to dissolve, and then added dropwise a solution of 2-isopropyl-4-methyl-pyridin-3-amine (1.0 g, 6.7 mmol) in tetrahydrofuran (5 mL).
- the fourth step is the synthesis of 4,6,7-trichloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one
- the eighth step 7 (2-Fluoro-6-methoxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-4-((S)-2-methyl Synthesis of piperazin-1-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile
- the first step Synthesis of 5-bromo-1,3-lutidine-2(1H)-one
- the fourth step 1- (2-isopropyl-4-methylpyridin-3-yl)-7-(2-methoxyphenyl)-2-oxo-4-(2,7-diazepine Synthesis of Spiro[4.4]nonan-2-yl)-1,2-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile
- the fifth step 4-(7-Acryloyl-2,7-diazaspiro[4.4]nonan-2-yl)-1-(2-isopropyl-4-methylpyridin-3-yl)- 7-(2-Methoxyphenyl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile
- the fourth step 1- (2-isopropyl-4-methylpyridin-3-yl)-7-(2-methoxyphenyl)-2-oxo-4-(2,7-diazepine Synthesis of Spiro[3.5]nonan-7-yl)-1,2-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile
- the first step 5-(6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3 Synthesis of -d]pyrimidin-4-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate tert-butyl ester
- the first step the synthesis of methyl 4-amino-5-bromo-2-fluorobenzoate
- the aqueous phase was extracted with ethyl acetate (50.0 mL).
- the organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and spin-dried under reduced pressure.
- the filter cake was dried under vacuum at 60° C. for 12 h to obtain the title compound as an off-white solid (7.30 g, yield 81.3%).
- the seventh step The synthesis of 6-bromo-4-chloro-7-iodo-1-(2-isopropyl-4-methylpyridin-3-yl)quinazolin-2(1H)-one
- 6-Bromo-4-chloro-7-iodo-1-(2-isopropyl-4-methylpyridin-3-yl)quinazolin-2(1H)-one (2.07g) was successively added to the reaction flask , 3.99mmol), acetonitrile (30mL), N,N-diisopropylethylamine (1.03g, 7.97mmol) and (S)-3-methylpiperazine-1-carboxylate tert-butyl ester (0.80g, 3.99 mmol).
- the reaction system was heated to 80°C for 2h.
- the fourth step 1- (2-isopropyl-4-methylpyridin-3-yl)-7-(2-methoxyphenyl)-2-oxo-4-(2,6-diazepine Synthesis of Spiro[3.3]heptan-2-yl)-1,2-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile
- the first step 7 (2-Fluoro-6-methoxyphenyl)-4-((S)-4-(2-fluoroacryloyl)-2-methylpiperazin-1-yl)-1- Synthesis of (2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile
- the first step 5-(6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3 Synthesis of -d]pyrimidin-4-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylic acid tert-butyl ester
- the third step 5-(6-cyano-7-(2-fluoro-5-methylphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo Synthesis of -1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylic acid tert-butyl ester
- the second step 4-(6-Chloro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-di Synthesis of Hydropyrido[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-7-carboxylic acid tert-butyl ester
- the third step 4-(6-cyano-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-di Synthesis of Hydropyrido[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-7-carboxylic acid tert-butyl ester
- the fourth step 7 (2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-4-(4,7-diazaspiro[ Synthesis of 2.5]octan-4-yl)-1,2-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile
- the fifth step 4-(7-acryloyl-4,7-diazaspiro[2.5]octan-4-yl)-7-(2-fluorophenyl)-1-(2-isopropyl-4 Synthesis of -methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile
- the third step 1- (2-isopropyl-4-methylpyridin-3-yl)-7-(5-methyl-1H-indazol-4-yl)-4-((S)-2- Synthesis of Methylpiperazin-1-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile
- the fourth step 1- (2-isopropyl-4-methylpyridin-3-yl)-7-(2-methoxy-3-methylphenyl)-2-oxo-4-(4, Synthesis of 7-diazaspiro[2.5]octan-4-yl)-1,2-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile
- 6-Bromo-7-iodo-1-(2-isopropyl-4-methylpyridin-3-yl)quinazoline-2,4(1H,3H)-dione (1.00 g, 2.00 mmol), (2-fluoro-5-methylphenyl)boronic acid (0.37 g, 2.40 mmol), sodium carbonate (0.64 g, 6.00 mmol), tetrakis(triphenylphosphine)palladium (0.12 g, 0.10 g mmol), 1,4-dioxane (15.0 mL) and water (3.5 mL).
- the reaction system was heated to 100°C under nitrogen protection for overnight reaction. After the reaction was completed, it was cooled to room temperature and filtered.
- the first step 4-(6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3 Synthesis of -d]pyrimidin-4-yl)-3,5-dimethylpiperazine-1-carboxylate tert-butyl ester
Abstract
L'invention concerne un dérivé de pyrimidone et son utilisation dans un médicament. Plus particulièrement, la présente invention concerne un nouveau dérivé de pyrimidone et une composition pharmaceutique contenant un tel composé. La présente invention concerne en outre un procédé de préparation du composé et de la composition pharmaceutique, une utilisation dans la préparation d'un médicament pour traiter des maladies et/ou des symptômes à médiation par KRAS G12C, et en particulier une utilisation dans la préparation d'un médicament pour traiter le cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011501090.4 | 2020-12-17 | ||
CN202011501090 | 2020-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022127847A1 true WO2022127847A1 (fr) | 2022-06-23 |
Family
ID=81991997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/138693 WO2022127847A1 (fr) | 2020-12-17 | 2021-12-16 | Dérivé de pyrimidone et son utilisation dans un médicament |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114644628A (fr) |
WO (1) | WO2022127847A1 (fr) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106488910A (zh) * | 2013-10-10 | 2017-03-08 | 亚瑞克西斯制药公司 | Kras g12c的抑制剂 |
CN107849022A (zh) * | 2015-04-10 | 2018-03-27 | 亚瑞克西斯制药公司 | 取代的喹唑啉化合物和其使用方法 |
WO2018119183A2 (fr) * | 2016-12-22 | 2018-06-28 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
WO2018217651A1 (fr) * | 2017-05-22 | 2018-11-29 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
WO2019051291A1 (fr) * | 2017-09-08 | 2019-03-14 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
WO2020239077A1 (fr) * | 2019-05-29 | 2020-12-03 | 上海翰森生物医药科技有限公司 | Régulateur dérivé hétérocyclique contenant de l'azote, son procédé de préparation et son application |
-
2021
- 2021-12-16 CN CN202111545576.2A patent/CN114644628A/zh active Pending
- 2021-12-16 WO PCT/CN2021/138693 patent/WO2022127847A1/fr active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106488910A (zh) * | 2013-10-10 | 2017-03-08 | 亚瑞克西斯制药公司 | Kras g12c的抑制剂 |
CN107849022A (zh) * | 2015-04-10 | 2018-03-27 | 亚瑞克西斯制药公司 | 取代的喹唑啉化合物和其使用方法 |
WO2018119183A2 (fr) * | 2016-12-22 | 2018-06-28 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
WO2018217651A1 (fr) * | 2017-05-22 | 2018-11-29 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
WO2019051291A1 (fr) * | 2017-09-08 | 2019-03-14 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
WO2020239077A1 (fr) * | 2019-05-29 | 2020-12-03 | 上海翰森生物医药科技有限公司 | Régulateur dérivé hétérocyclique contenant de l'azote, son procédé de préparation et son application |
Also Published As
Publication number | Publication date |
---|---|
CN114644628A (zh) | 2022-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105732636B (zh) | 杂芳化合物及其在药物中的应用 | |
CN107011348B (zh) | 作为btk活性的抑制剂的杂芳基吡啶酮和氮杂-吡啶酮化合物 | |
CN113135924B (zh) | 嘧啶衍生物及其在药物中的应用 | |
TW202140450A (zh) | 用於癌症治療的kras抑制劑 | |
WO2022037560A1 (fr) | Dérivé de pyrimidone et son utilisation dans un médicament | |
CN106749233B (zh) | 一类磺酰胺衍生物及其应用 | |
CN105732637B (zh) | 杂芳化合物及其在药物中的应用 | |
WO2021143680A1 (fr) | Dérivé hétéroaryle, son procédé de préparation et son utilisation | |
WO2012058193A1 (fr) | Activité de l'enzyme kinase à répétition riche en leucine | |
CN107344940B (zh) | Btk抑制剂及其用途 | |
WO2015158310A1 (fr) | Inhibiteur de tyrosine kinase et ses utilisations | |
TWI683811B (zh) | 二氫噠嗪-3,5-二酮衍生物 | |
JP2014506930A (ja) | セリン/トレオニンキナーゼインヒビター | |
WO2017071516A1 (fr) | Inhibiteur de kinase et procédé pour sa préparation et utilisation pharmaceutique correspondante | |
KR20230035036A (ko) | 이중 키나제-브로모도메인 억제제 | |
WO2021057970A1 (fr) | Inhibiteur de ret, composition pharmaceutique associée et utilisation associée | |
WO2022033544A1 (fr) | Composé hétéroaryle substitué, composition et utilisation associées | |
WO2021057963A1 (fr) | Inhibiteur de ret, composition pharmaceutique comprenant celui-ci et utilisation associée | |
WO2021043209A1 (fr) | Inhibiteur de ret, composition pharmaceutique et utilisation associée | |
CN108948019B (zh) | 黏着斑激酶抑制剂及其用途 | |
TWI692358B (zh) | 含有鈉依賴性磷酸輸送蛋白抑制劑之醫藥 | |
WO2022127847A1 (fr) | Dérivé de pyrimidone et son utilisation dans un médicament | |
CN113620944A (zh) | 新型的ret抑制剂、其药物组合物及其用途 | |
CN108299436B (zh) | 黄嘌呤类化合物及其药物组合物和应用 | |
CN113620945A (zh) | Ret抑制剂、其药物组合物及其在药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21905773 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21905773 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21905773 Country of ref document: EP Kind code of ref document: A1 |